<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28114909</article-id><article-id pub-id-type="pmc">5259892</article-id><article-id pub-id-type="publisher-id">3064</article-id><article-id pub-id-type="doi">10.1186/s12885-017-3064-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Augustin</surname><given-names>Livia S.A.</given-names></name><address><phone>081-590 3395</phone><email>livia.augustin@utoronto.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Libra</surname><given-names>Massimo</given-names></name><address><email>m.libra@unict.it</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Crispo</surname><given-names>Anna</given-names></name><address><email>anna.crispo@tin.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grimaldi</surname><given-names>Maria</given-names></name><address><email>m.grimaldi@istitutotumori.na.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>De Laurentiis</surname><given-names>Michele</given-names></name><address><email>m.delaurentiis@istitutotumori.na.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rinaldo</surname><given-names>Massimo</given-names></name><address><email>massimo.rinaldo@tiscali.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Aiuto</surname><given-names>Massimiliano</given-names></name><address><email>massimiliano.daiuto@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Catalano</surname><given-names>Francesca</given-names></name><address><email>fcatalano1968@tiscali.it</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Banna</surname><given-names>Giuseppe</given-names></name><address><email>gbanna@yahoo.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ferrau&#x02019;</surname><given-names>Francesco</given-names></name><address><email>francescoferrau@tin.it</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rossello</surname><given-names>Rosalba</given-names></name><address><email>rosalbarossello@alice.it</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Serraino</surname><given-names>Diego</given-names></name><address><email>serrainod@cro.it</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Bidoli</surname><given-names>Ettore</given-names></name><address><email>bidolie@cro.it</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Massarut</surname><given-names>Samuele</given-names></name><address><email>smassarut@cro.it</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Guglielmo</given-names></name><address><email>guglielmo.thomas@outlook.it</email></address><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Gatti</surname><given-names>Davide</given-names></name><address><email>davide.gatti@univr.it</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Cavalcanti</surname><given-names>Ernesta</given-names></name><address><email>e.cavalcanti@istitutotumori.na.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pinto</surname><given-names>Monica</given-names></name><address><email>m.pinto@istitutotumori.na.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Riccardi</surname><given-names>Gabriele</given-names></name><address><email>riccardi@unina.it</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Vidgen</surname><given-names>Edward</given-names></name><address><email>ed.vidgen@utoronto.ca</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Kendall</surname><given-names>Cyril W.C.</given-names></name><address><email>cyril.kendall@utoronto.ca</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Jenkins</surname><given-names>David J.A.</given-names></name><address><email>NutritionProject@smh.ca</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Ciliberto</surname><given-names>Gennaro</given-names></name><address><email>gennaro.ciliberto@ifo.gov.it</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Montella</surname><given-names>Maurizio</given-names></name><address><email>m.montella@istitutotumori.na.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.414603.4</institution-id><institution>National Cancer Institute Istituto Nazionale Tumori &#x0201c;Fondazione Giovanni Pascale&#x0201d;, </institution><institution>IRCCS, </institution></institution-wrap>Naples, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.415502.7</institution-id><institution>Clinical Nutrition and Risk Factor Modification Centre, </institution><institution>St. Michael&#x02019;s Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1969</institution-id><institution-id institution-id-type="GRID">grid.8158.4</institution-id><institution>Department of Biomedical and Biotechnological Sciences Oncologic, Clinical and General Pathology Section, </institution><institution>University of Catania, </institution></institution-wrap>Catania, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1759 8037</institution-id><institution-id institution-id-type="GRID">grid.413340.1</institution-id><institution/><institution>Cannizzaro Hospital, </institution></institution-wrap>Catania, Italy </aff><aff id="Aff5"><label>5</label>San Vincenzo Hospital, Taormina, Italy </aff><aff id="Aff6"><label>6</label>National Cancer Institute CRO, Aviano, Italy </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2200 8888</institution-id><institution-id institution-id-type="GRID">grid.9841.4</institution-id><institution/><institution>Seconda Universita&#x02019; di Napoli, </institution></institution-wrap>Naples, Italy </aff><aff id="Aff8"><label>8</label>Clinica Mediterranea SpA, Naples, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1763 1124</institution-id><institution-id institution-id-type="GRID">grid.5611.3</institution-id><institution>Rheumatology Unit, </institution><institution>University of Verona, </institution></institution-wrap>Verona, Italy </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution>Department of Clinical Medicine and Surgery, </institution><institution>Federico II University, </institution></institution-wrap>Naples, Italy </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Department of Nutritional Sciences, Faculty of Medicine, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2154 235X</institution-id><institution-id institution-id-type="GRID">grid.25152.31</institution-id><institution>College of Pharmacy and Nutrition, </institution><institution>University of Saskatchewan, </institution></institution-wrap>Saskatoon, Canada </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.415502.7</institution-id><institution>Division of Endocrinology and Metabolism, </institution><institution>St. Michael&#x02019;s Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.415502.7</institution-id><institution>Li Ka Shing Knowledge Institute, </institution><institution>St. Michael&#x02019;s Hospital, </institution></institution-wrap>Toronto, Canada </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1760 5276</institution-id><institution-id institution-id-type="GRID">grid.417520.5</institution-id><institution/><institution>National Cancer Institute IRCCS Istituto Nazionale Tumori &#x0201c;Regina Elena&#x0201d;, </institution></institution-wrap>Rome, Italy </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>69</elocation-id><history><date date-type="received"><day>21</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Mechanisms influencing breast cancer (BC) development and recurrence include hyperglycemia, hyperinsulinemia, high insulin-like growth factor-1, high circulating estrogen, inflammation and impaired cellular differentiation/apoptosis. A lifestyle program that targets all the above mechanisms may be warranted. Low glycemic index (GI) foods produce lower post-prandial glucose and insulin responses and have been associated with lower BC risk. Moderate physical activity post-diagnosis reduces BC recurrence and mortality, partly explained by reduced insulin and estrogen levels. Vitamin D increases cell differentiation/apoptosis and high serum vitamin D levels improve BC survival. Yet no trial has evaluated the combined effect of a low GI diet, moderate physical activity and vitamin D supplementation on BC recurrence in the context of a Mediterranean lifestyle setting.</p></sec><sec><title>Methods</title><p>Women (30-74&#x000a0;yr) who had undergone surgery for primary histologically confirmed BC (stages I-III) within the previous 12&#x000a0;months, in cancer centres in Italy, will be randomized to follow, for a maximum of 33&#x000a0;months, either a high intensity treatment (HIT) composed of low GI diet&#x02009;+&#x02009;exercise&#x02009;+&#x02009;vitamin D (60&#x000a0;ng/mL serum concentration) or a lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern&#x02009;+&#x02009;vitamin D to avoid insufficiency. Both interventions are on a background of a Mediterranean diet. Considering a 20% recurrence rate within 3&#x000a0;years for BC cases and a predicted rate of 10% in the HIT group, with power of 80% and two-sided alpha of 0.05, the subject number required will be 506 (<italic>n</italic>&#x02009;=&#x02009;253 in each arm). Clinic visits will be scheduled every 3&#x000a0;months. Dietary and exercise counselling and vitamin D supplements will be given at each clinic visit when blood samples, anthropometric measures and 7-day food records will be collected.</p></sec><sec><title>Discussion</title><p>DEDiCa study aims to reduce BC recurrence in women with BC using a lifestyle approach with additional vitamin D and to investigate possible cardio-metabolic benefits as well as epigenetic modifications according to lifestyle changes. Given the supporting evidence and safety of the components of our intervention we believe it is feasible and urgent to test it in cancer patients.</p></sec><sec><title>Trial registration</title><p>May 11, 2016; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">NCT02786875</ext-link>. </p></sec><sec><title>EudraCT Number</title><p>2015-005147-14</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dietary glycemic index</kwd><kwd>Mediterranean diet</kwd><kwd>Exercise</kwd><kwd>Vitamin D</kwd><kwd>Breast cancer recurrence</kwd><kwd>Disease-free survival</kwd><kwd>Cardiovascular disease</kwd><kwd>Diabetes</kwd><kwd>Risk factors</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003196</institution-id><institution>Ministero della Salute</institution></institution-wrap></funding-source><award-id>PE-2013-02358099</award-id><principal-award-recipient><name><surname>Montella</surname><given-names>Maurizio</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Breast cancer (BC) is the most common cancer in women and the 5-year survival rate in Europe is 82% suggesting a considerable residual risk [<xref ref-type="bibr" rid="CR1">1</xref>]. BC is associated also with other chronic conditions including type two diabetes which may increase the risk of BC recurrence [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>] and many BC patients are at increased risk for cardiovascular disease (CVD) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Mechanisms of BC appear to be linked to sex hormones, impairment in glucose metabolism, hyperglycemia, hyperinsulinemia, insulin-like growth factors (IGF), inflammation, oxidative stress and impaired cell apoptosis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Current advice to BC survivors suggests adopting cancer prevention strategies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], however there is no consensus on the effectiveness of lifestyle programs in women with BC [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] mostly due to lack of sufficient evidence [<xref ref-type="bibr" rid="CR13">13</xref>]. The rationale for the study is to target several mechanisms of cancer suppression or proliferation, with a healthy diet and exercise program, to avoid low vitamin D levels in order to obtain maximal efficacy of the lifestyle program, and concomitantly to offer maximal CVD and diabetes protection. Dietary carbohydrates are the main food components to affect glycemia and insulinemia. The glycemic index (GI) is able to capture the difference between those that increase glycemia the most (high GI foods) and those that increase it the least (low GI foods) [<xref ref-type="bibr" rid="CR14">14</xref>]. Low GI foods lower the glycemic and insulinemic potential of the diet and have been shown to reduce the risk of several cancers particularly diabetes-related cancers including BC [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] and some evidence suggests they also correlate with lower recurrence [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, low GI diets have been inversely associated with risk of type two diabetes [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and CVD [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] and favourably modified blood glucose [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>], blood lipids [<xref ref-type="bibr" rid="CR27">27</xref>], inflammatory markers [<xref ref-type="bibr" rid="CR28">28</xref>], oxidative damage [<xref ref-type="bibr" rid="CR29">29</xref>], body weight [<xref ref-type="bibr" rid="CR30">30</xref>] and IGF binding proteins [<xref ref-type="bibr" rid="CR31">31</xref>], all factors relevant to carcinogenesis, diabetes and CVD. Our previous studies in Italy have shown significant risk reduction of 40% with a low GI diet compared to a high GI diet in BC primary prevention [<xref ref-type="bibr" rid="CR18">18</xref>]. Physical activity is one of the mainstays of primary prevention of cancer and it is also included in guidelines for BC survivors (at least 150&#x000a0;minutes per week) mainly to reduce complications such as lower muscle strength and risk of depression [<xref ref-type="bibr" rid="CR13">13</xref>]. However, physical activity after BC diagnosis has also been shown to reduce the risk of BC mortality by 40&#x02013;50% particularly when it is of moderate intensity such as 30&#x000a0;minutes of brisk walking per day [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>] an effect possibly modulated partly by insulin economy improvements in reduced insulin, insulin-like growth factors and estrogen levels [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>To maximize lifestyle changes it may be useful to avoid vitamin deficiencies, particularly vitamin D deficiency which has been linked to higher breast cancer risk [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Vitamin D alters genes implicated in cellular growth, affecting proliferation, apoptosis, differentiation, angiogenesis, invasion and metastasis [<xref ref-type="bibr" rid="CR37">37</xref>]. Preliminary studies suggest that normal-high ranges of serum vitamin D levels improve BC survival [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p>Low glycemic index diet, exercise and vitamin D intake, in addition to determining metabolic changes and benefits for cancer patients, may be able to change the tumor microenvironment and lead to epigenetic modifications [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. In this context, microRNAs (miRNAs), small noncoding RNA molecules, may play a fundamental role in modulating gene expression and breast cancer progression [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The evaluation of circulating miRNAs is useful to identify the change of specific miRNAs involved in cancer pathways and predict the development of recurrence in breast cancer patients.</p><p>A lifestyle program that targets all the above mechanisms may be warranted. To our knowledge no trial has evaluated the combined effect of a lifestyle program with a healthy diet focusing on low GI, additional physical activity and supplemental vitamin D on BC recurrence and complications in the context of a Mediterranean dietary setting.</p></sec><sec id="Sec2"><title>Methods/Design</title><sec id="Sec3"><title>Aims and objectives</title><p>DEDiCa study aims primarily at reducing BC recurrence in women with BC using a lifestyle approach with additional vitamin D. The primary objective of DEDiCa study is to determine the effect of a 33-month program combining advice on diet, exercise and supplemental vitamin D, on reducing BC recurrence rates or increasing disease-free survival (DFS). Secondary objectives are to improve markers of diabetes risk and management for those who already have diabetes, to improve cardiometabolic health and quality of life (QoL) and to investigate whether changes in microRNA correlate with changes in lifestyle.</p></sec><sec id="Sec4"><title>Study design</title><p>This is a randomized clinical trial targeting women with BC stages I-III within 12&#x000a0;months from BC surgery (see Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> for details). The study involves at least five cancer centers in Italy (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) and it started on Oct 10<sup>th</sup>, 2016. Consenting participants are randomized to either a high intensity program (HIT) or a lower intensity program (LITE, positive control). The endpoints will be assessed at baseline and every three months until the end of the study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion criteria</th><th>Exclusion criteria</th></tr></thead><tbody><tr><td>1. Women with primary diagnosis of histologically confirmed breast cancer (T1 with Ki67&#x02009;&#x02265;&#x02009;30%, T2, T3 without metastasis) within 12&#x000a0;months from diagnosis.<break/>2. Age&#x02009;&#x02265;&#x02009;30 and&#x02009;&#x0003c;&#x02009;75&#x000a0;years.<break/>3. Patients who are able to comprehend and are willing to sign the consent form and are able to adhere to the protocol including scheduled clinic visits and assigned treatment.</td><td>1. Patients who do not possess the inclusion criteria for this study.<break/>2. Patients with sarcoidosis or other granulomatous diseases or with hypercalcemia (Ca&#x02009;&#x0003e;&#x02009;11&#x000a0;mg/dL).<break/>3. Patients with any previous or current concomitant malignant cancer.<break/>4. Pregnant or lactating women.<break/>5. Patients with AIDS diagnosis<break/>6. Patients with severe renal insufficiency<break/>7. Patients with kidney stones (nephrocalcinosis or nephrolithiasis)<break/>8. Patients participating in other lifestyle clinical trials</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Details of inclusion criteria n. 1</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Stage</th><th>Primary Tumor</th><th>Lymph nodes</th><th>Metastasis</th><th>Ki-67</th></tr></thead><tbody><tr><td>I</td><td>T1b, T1c</td><td>N0</td><td>M0</td><td>&#x02265;30%</td></tr><tr><td>IIA</td><td>T1a, T1b, T1c<break/>T2</td><td>N1<break/>N0</td><td>M0<break/>M0</td><td>any</td></tr><tr><td>IIB</td><td>T2<break/>T3</td><td>N1<break/>N0</td><td>M0<break/>M0</td><td>any</td></tr><tr><td>IIIA</td><td>T1a, T1b, T1c<break/>T2<break/>T3</td><td>N2<break/>N2<break/>N1, N2</td><td>M0<break/>M0<break/>M0</td><td>any</td></tr><tr><td>IIIC</td><td>T1a, T1b, T1c<break/>T2<break/>T3</td><td>N3<break/>N3<break/>N3</td><td>M0<break/>M0<break/>M0</td><td>any</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>List of recruiting centres in Italy</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Recruiting centres</td></tr><tr><td align="center">&#x02022; Coordinating Centre: National Cancer Institute Fondazione G. Pascale (Napoli);<break/>&#x025cb; Via Mariano Semmola &#x02013; 80131 Napoli<break/>&#x025cb; Tel: 081/5903395<break/>&#x025cb; Email: epidemiologia@istitutotumori.na.it<break/>&#x025cb; <ext-link ext-link-type="uri" xlink:href="http://www.istitutotumori.na.it/">www.istitutotumori.na.it/</ext-link>
<break/>&#x02022; Clinica Mediterranea, Senology Unit; Via Orazio, 2&#x02013;80122 Napoli; <ext-link ext-link-type="uri" xlink:href="http://www.clinicamediterranea.it/">www.clinicamediterranea.it/</ext-link>
<break/>&#x02022; Cannizzaro Hospital, Senology Unit; Via Messina, 829&#x02013;95126 Catania; <ext-link ext-link-type="uri" xlink:href="http://www.aocannizzaro.it/">www.aocannizzaro.it/</ext-link>
<break/>&#x02022; San Vincenzo Hospital of Taormina, Oncology Unit; Via Sirina, 98039 Taormina (Messina); <ext-link ext-link-type="uri" xlink:href="http://www.oncologiataormina.it/">www.oncologiataormina.it/</ext-link>
<break/>&#x02022; National Cancer Institute CRO Aviano; Via Franco Gallini, 2&#x02013;33081 Aviano (Pordenone); <ext-link ext-link-type="uri" xlink:href="http://www.cro.it">www.cro.it</ext-link>
</td></tr></tbody></table></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Schematic representation of DEDiCa study protocol</p></caption><graphic xlink:href="12885_2017_3064_Fig1_HTML" id="MO1"/></fig>
</p><p>To improve compliance participants on both sides will be followed equally with blood tests and clinic visits and will be equally offered general advice on a healthy Mediterranean diet and physical activity, step counters and vitamin D supplements to avoid insufficiency. Participants in the HIT group will additionally receive dietary counselling on how to reduce the GI of their diet, packages of pasta, more in-depth advice on exercise and more vitamin D supplements compared to the LITE group.</p><p>This study was approved by the ethic board of the Italian Medicine Agency (AIFA), and of each recruiting hospital: National Cancer Institute &#x0201c;Fondazione Giovanni Pascale&#x0201d; in Naples, Azienda Ospedaliera per l&#x02019;Emergenza Ospedale Cannizzaro in Catania, Azienda Ospedaliera Universitaria Policlinico &#x0201c;G. Martino&#x0201d; in Messina for San Vincenzo Hospital of Taormina, Comitato Etico Campania Centro ASL NA1 Centro for Clinica Mediterranea in Naples. The study has been registered with ClinicalTrials.gov (registration date and number: May 11, 2016; NCT02786875).</p></sec><sec id="Sec5"><title>Participants</title><p>Women who had undergone surgery for primary histologically confirmed BC, stages I-III (see Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> for details), within the previous 12&#x000a0;months in cancer centres in Italy, who are between the ages 30&#x02013;74&#x000a0;years and have no contraindications to participate in this study will be eligible to participate. Eligibility is confirmed by central reviewing of medical records and pathology reports. The inclusion and exclusion criteria are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. To participate in the study each potential participant is required to read and sign the study information/consent form at baseline.</p></sec><sec id="Sec6"><title>Recruitment and randomization</title><p>Eligible participants are recruited in five oncologic centres in Italy (four in Southern Italy and one in Northern Italy). Details of the recruiting centres can be found in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Eligible participants are contacted either by phone or during one of their follow-up visits and offered to hear more about the study during an information session (either group session or a one-to-one session to accommodate all needs). Eligible participants are explained the study details and are given an informed consent document to take home which they bring back at the baseline visit. At the baseline visit, after obtaining written consent the participant is sent for a blood test and other measurements, is randomized to one of the two arms of the study, receives the advice on the program according to her randomization arm and is given the next appointment slip. Participants are contacted by phone monthly for the first three months and once between visits afterwards. Study visits are scheduled every 3&#x000a0;months until end of study (33&#x000a0;months).</p><p>Randomization is done electronically in real time for all recruiting centres and is stratified by stage (I/IIA vs. IIB/IIIA) and age (&#x0003c;50&#x000a0;yrs or &#x02265;50&#x000a0;yrs) at diagnosis and is based on a permuted block design with block size of 4. Stratification by stage and age is done because we expect these variables to affect the outcomes. To prevent any possible study bias the randomization sequence will be done off-site by a third party statistician (Contract Research Organization, Naples, Italy) who will not have contacts with the study participants. The PI is blinded to the randomization of the study participants but not the staff involved in the clinic visits.</p></sec><sec id="Sec7"><title>Interventions</title><p>Eligible and consenting subjects are randomized to either one of the two treatment programs (higher or lower intensity):<list list-type="bullet"><list-item><p>
<bold>Higher intensity (HIT) arm (test)</bold>: low GI diet&#x02009;+&#x02009;exercise&#x02009;+&#x02009;vitamin D.<list list-type="order"><list-item><p>All carbohydrate foods advised will be low GI choices (GI&#x02009;&#x0003c;&#x02009;70, on the bread scale), e.g. legumes, pasta al dente, barley, low GI rice, low GI bread, oat, apples, oranges, berries, avocado and nuts.</p></list-item><list-item><p>Brisk walk of at least 30&#x000a0;min per day (or approximately 5000 steps) more than the habitual physical activity.</p></list-item><list-item><p>Vitamin D supplement (cholecalciferol) up to 4000&#x000a0;IU/day to reach the upper end of normal blood levels of 25(OH)D (60&#x000a0;ng/ml).</p></list-item></list>
</p></list-item><list-item><p>
<underline>Lower intensity (LITE) arm (positive control)</underline>: general recommendations for a healthy diet and physical activity. Vitamin D (cholecalciferol) will be given only if hypovitaminosis D is detected to bring blood levels up to normal ranges of 30&#x000a0;ng/mL.</p></list-item></list>
</p><p>Both groups will be counselled to follow a healthy Mediterranean diet (&#x02265;5 servings vegetable/fruit per day, &#x02264;1 serving red meat/cold cuts per week, &#x0003c;7% saturated fat).</p><p>Treatment evaluations are conducted every three months at each clinic visit and include all three components of the treatment (diet, exercise, vitamin D). Seven-day food records is collected from each patient which is filled a week before the clinic visit. The information in the food record is reviewed by the nutritionist staff with the patient and subsequently inserted in a diet analysis program (WinFood Medimatica, Version 3.9.0). Daily means of GI, energy intake, macro- and micro-nutrients and food groups will be obtained from WinFood and periodically evaluated to ensure adherence to the dietary advice. The physical activity component is measured with a step counter with 7-day memory (OMRON Walking Style IV) and with a questionnaire. Participants bring the step counter back at each clinic visit and the 7-day values are recorded by the research staff. Vitamin D is evaluated by blood analysis of 25(OH)D every three months, the dose reviewed at each clinic visit and changed if necessary to reach the group target (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). QoL is measured with questionnaires specifically made for cancer patients (EQ-5D-3&#x000a0;L, EORTC QLQ-C30 e EORTC QLQ-BC23) [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>].<table-wrap id="Tab4"><label>Table 4</label><caption><p>Vitamin D algorithm</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Blood levels (ng/ml)</th><th>Oral dose (IU)</th><th>Treatment duration</th></tr></thead><tbody><tr><td colspan="3">Group A (target: 60&#x000a0;ng/ml):</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;10</td><td>75 000 at study visit<break/>+4000/day</td><td>3&#x000a0;months<break/>then re-evaluate</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;10-20</td><td>50 000 at study visit<break/>+4000/day</td><td>3&#x000a0;months<break/>then re-evaluate</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;20-30</td><td>25 000 at study visit<break/>+4000/day</td><td>3&#x000a0;months<break/>then re-evaluate</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;30</td><td>4000/day</td><td>3&#x000a0;months<break/>then re-evaluate</td></tr><tr><td>&#x02003;60-80</td><td>change to 1000&#x000a0;IU/day</td><td>3&#x000a0;months<break/>then re-evaluate</td></tr><tr><td colspan="3">Group B (target: 30&#x000a0;ng/ml):</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;10</td><td>100 000 at study visit</td><td>Re-evaluate after 3&#x000a0;months</td></tr><tr><td>&#x02003;&#x02009;&#x02264;&#x02009;20</td><td>75 000 at study visit</td><td>Re-evaluate after 3&#x000a0;months</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;20-25</td><td>50 000 at study visit</td><td>Re-evaluate after 3&#x000a0;months</td></tr><tr><td>&#x02003;&#x02009;&#x0003e;&#x02009;25-29</td><td>25 000 at study visit</td><td>Re-evaluate after 3&#x000a0;months</td></tr><tr><td>&#x02003;&#x02009;&#x02265;&#x02009;30</td><td>0</td><td>Re-evaluate after 3&#x000a0;months</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Outcome measures</title><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> depicts the timing and frequency of all study measures. Blood analyses, blood pressure, anthropometric measurements and 7-day food records are taken at baseline and every 3&#x000a0;months afterwards until end of study (up to 33&#x000a0;months). Complete blood analyses are done at baseline, 1&#x000a0;year and end of study while blood analysis pertinent to the treatment are done every three months (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The primary outcome is the percentage of patients alive at end of study without BC recurrence (disease in the same or opposite breast or any metastasis). The primary outcome is assessed at each collaborating centre by the collaborating oncologist and confirmed by hospital pathological results which are communicated to the coordinating centre. Secondary end points include glycemic control including blood glucose and glycated hemoglobin (HbA1c), cardiometabolic variables including body weight, waist circumference, body mass index (BMI), blood pressure, C-reactive protein (CRP) and blood lipids, hormonal measures including insulin, insulin-like growth factor-1 (IGF-1), estradiol, testosterone and sex hormone binding globulin (SHBG), and epigenetic markers (microRNA). Program adherence and any difficulty noticed, medications and medication changes, as well as any unusual or adverse events, including illness or stressful issues, that occurred since the last clinic visit are recorded in detail.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Blood analyses performed during the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameters</th><th>Baseline, 12 mo and study end</th><th>Every 3&#x000a0;months</th></tr></thead><tbody><tr><td>25(OH)D</td><td>x</td><td>x</td></tr><tr><td>Calcium</td><td>x</td><td>x</td></tr><tr><td>Glucose</td><td>x</td><td>x</td></tr><tr><td>HbA1c</td><td>x</td><td>x</td></tr><tr><td>Insulin</td><td>x</td><td/></tr><tr><td>Triglycerides</td><td>x</td><td/></tr><tr><td>Total Cholesterol</td><td>x</td><td/></tr><tr><td>&#x02003;LDL-C</td><td>x</td><td/></tr><tr><td>&#x02003;HDL-C</td><td>x</td><td/></tr><tr><td>AST/ALT</td><td>x</td><td/></tr><tr><td>CRP</td><td>x</td><td/></tr><tr><td>Estradiol</td><td>x</td><td/></tr><tr><td>Testosterone</td><td>x</td><td/></tr><tr><td>SHBG</td><td>x</td><td/></tr><tr><td>IGF-1</td><td>x</td><td/></tr><tr><td>microRNA</td><td>x</td><td/></tr><tr><td>For future analyses</td><td>x</td><td>x</td></tr></tbody></table><table-wrap-foot><p>
<italic>AST/ALT</italic>: aspartate transaminase/alanine transaminase, <italic>CRP</italic>: C-reactive protein, <italic>HbA1c</italic>: hemoglobin A1c, <italic>HDL-C</italic>: high density lipoprotein cholesterol, <italic>IGF-1</italic>: insulin-like growth factor-1, <italic>LDL-C</italic>: low density lipoprotein cholesterol, <italic>SHBG</italic>: sex hormone binding globulin, <italic>25(OH)D</italic>: 25-hydroxyvitamin D.</p></table-wrap-foot></table-wrap>
</p><p>Blood samples and all information regarding the patient are sent to the coordinating centre where blood samples are centrally analyzed and information entered electronically and statistically analyzed for the interim and end of study reports.</p></sec><sec id="Sec9"><title>Biochemical analyses</title><p>Serum vitamin D and IGF-1 are analyzed using DiaSorin kits on Liaison XL analyzer (DiaSorin) by chemiluminescent method (CLIA). The HbA1c value is analyzed using whole blood collected in EDTA Vacutainer tubes (Vacutainer; Becton, Dickinson and Co) by a turbidimetric inhibition latex immunoassay (TINA QUANT Roche Diagnostics) on Cobas C6000 analyzer (Roche). Serum glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), are measured using reagents and analyzer (Cobas C6000) by Roche Diagnostics according to the manufacturer&#x02019;s instructions. Serum insulin, estradiol, testosterone and SHBG are performed on the same analyzer by electro-chemiluminescent method (ECLIA). Nephelometric quantification of CRP is performed on BNP ProSpec nephelometer (Siemens Healthcare Diagnostics) according to the manufacturer&#x02019;s instructions. Serum samples are obtained by blood collected in Vacutainer tubes without anticoagulant (Becton, Dickinson and Co) and analyzed within 24&#x000a0;hours. All analytes are measured in the coordinating hospital routine analytical laboratory undergoing quality control procedures.</p></sec><sec id="Sec10"><title>MicroRNA Analysis</title><p>Previous studies have demonstrated that microRNAs (miRNAs) are frequently dysregulated in human cancers, including BC [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] and may be modified by the glycemic load of the diet [<xref ref-type="bibr" rid="CR41">41</xref>]. Computational models are important for the understanding of biological systems [<xref ref-type="bibr" rid="CR52">52</xref>]. The following are the procedures to identify and analyze miRNA. These analyses will be conducted at the Laboratory of the Biomedical Sciences Department at the University of Catania (Italy).</p><sec id="Sec11"><title>Identification of plasma miRNA in BC</title><p>Plasma samples are randomly selected for the analysis by the Human Serum &#x00026; Plasma miScript miRNA PCR Array (Qiagen) that profiles the expression of 84 miRNAs. In this phase, miRNA expression patterns are analyzed in BC patients according to the lifestyle and dietary intake.</p></sec><sec id="Sec12"><title>Circulating microRNA analysis</title><p>miRNAs can be easily purified from a number of patient body fluids. Several studies shown that miRNAs were present in serum and plasma and easily detectable by a sample of peripheral blood. Circulating miRNAs may be important players in the formation of the tumor microenvironment and metastatic evolution by promoting epithelial to mesenchymal transition (EMT) of tumor cells. RNA and miRNAs fraction are extracted from 200&#x000a0;&#x003bc;L of plasma are isolated by miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s recommendations Extracted miRNAs are reverse transcribed into cDNA and analyzed by miScript SYBR Green PCR Kit (Qiagen).</p></sec><sec id="Sec13"><title>Validation of circulating miRNAs in BC tissues</title><p>Data obtained in the previous two steps above are validated in tumor tissue samples to confirm the origin source of the circulating miRNA previously identified.</p></sec><sec id="Sec14"><title>miRNAs and epithelial mesenchymal transition (EMT)</title><p>miRNAs, a class of small non-coding RNA molecules that post-transcriptionally regulate gene expression, are attractive candidates for regulating stem cell self-renewal, cell fate decisions and cell plasticity. For this reason, miRNAs analysis is carried out to shed light on the post-transcriptional control of EMT and stemness.</p></sec><sec id="Sec15"><title>Analysis of EMT genes</title><p>Publicly available gene expression datasets are analyzed to identify pathways involved in EMT. For this reason a comparative analysis of expression of master regulators of EMT genes (Beta-Catenin, OPN, Twist1/2, Snail1/2, Zeb1/2, N-cad, Vim, E-cad and NGAL) will be performed. GSEA (Gene Set Enrichment Analysis <ext-link ext-link-type="uri" xlink:href="http://broad.mit.edu/gsea">http://broad.mit.edu/gsea</ext-link>) will assess whether the potential pathways involved in EMT, identified in the previous analysis, will be confirmed using a different computational approach. The key genes, representing the highly connected hubs in the identified networks, are assessed by qRT-PCR and IHC on selected archival tumor series to determine their diagnostic and prognostic value according to clinical information, lifestyle and dietary intake.</p></sec><sec id="Sec16"><title>MiRNAs and their role in modulating EMT</title><p>Validated miRNAs are analyzed by in silico approaches (miRanda, miRbase, TargetScan) to evaluate if EMT genes previously analyzed are included among their putative target genes. miRNAs here identified and their putative target genes are analyzed in BC tumor tissue, positive for canonical mesenchymal markers, such as Vimentin and N-cadherin. Evaluation of EMT markers are carried out by IHC followed by laser micro-dissection. Further functional experiments are performed to validate in silico considerations.</p></sec><sec id="Sec17"><title>Risk recurrence in BC by computational modeling</title><p>The development of a computational model based on agent based modelling, differential equations or Petri nets could lead to a validated tool able to predict the efficacy of the dietary regimen. The model is fit with data coming from the diet regiment components, diet effects, life style, and from plasma miRNAs analysis. miRNAs expression allows the model to be tuned to find evidences that may be relevant to predict the time and the probability of recurrence risk.</p></sec></sec><sec id="Sec18"><title>Sample size</title><p>Considering a 20% recurrence rate within 3&#x000a0;years in most collaborating centres for BC cases specified in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, and a predicted rate of 10% in the high intensity arm, with power of 80% and two-sided alpha of 0.05, the number of subjects are 506 (<italic>n</italic>&#x02009;=&#x02009;253 in each arm).</p></sec><sec id="Sec19"><title>Statistical analyses</title><p>All randomized patients will be analysed considering the &#x0201c;intention-to-treat&#x0201d; principle (ITT analysis). Results will be expressed as percentages or means&#x02009;&#x000b1;&#x02009;SEM or 95% confidence intervals (CI).</p><sec id="Sec20"><title>Primary analyses</title><p>The primary analyses will assess the between-treatment difference in BC recurrence measured as disease-free survival (DFS), calculated as the percentage of patients alive without recurrence of disease at study end (up to 33&#x000a0;months from randomization). BC recurrence is defined as the relapse of the disease or metastasis either in the same breast (including new positive lymph nodes), or the opposite breast or in distant organs. The duration of DFS in patients lost at follow-up will be censured at the date of the last day the patient was considered free of disease. Between-treatment differences in DFS will be analyzed by <italic>log-rank</italic> test. Kaplan-Meier curves will be provided to estimate median DFS and 95% CI. To address the impact of potential imbalance in prognostic factors we will repeat the primary analysis using the <italic>log-rank</italic> test stratified by stage, age, family history of BC, time since diagnosis, molecular subtype, medication use, smoking, baseline waist circumference and dietary variables (baseline GI, dietary fiber, saturated fat, vegetables/fruit, meat, sweets/desserts). Missing data for covariates will be handled by using the missing indicator method.</p></sec><sec id="Sec21"><title>Sensitivity analyses</title><p>To assess the robustness of our ITT primary analysis with possible missing data we will repeat the primary analysis using completers data only as well as per-protocol data only, using multiple imputation method to generate missing data in the stratification step. To assess the impact of participant-level factors on the primary outcome we will examine DFS separately in those who, at study end, have reached normo-glycemia (&#x0003c;110&#x000a0;mg/dl) and normal levels of HbA1c &#x0003c;6.0% versus those who have higher levels, in those who reached circulating 25(OH)D &#x02265;60&#x000a0;ng/ml versus those who reached &#x02264;30&#x000a0;ng/ml, in those who have lower versus those who have higher insulin levels (median will be used as cut-offs), in those who have good overall compliance on the three treatment components that is in the highest quantile of: low GI&#x02009;+&#x02009;number of daily steps&#x02009;+&#x02009;levels of 25(OH)D, versus those who have lower compliance. For these analyses study end is defined as the mean of the last three visits.</p></sec><sec id="Sec22"><title>Secondary analyses</title><p>The mean and standard error for each of the following variables will be determined for each study group. The change from baseline to end of study will be compared between groups using repeated measures ANOVA and using nonparametric tests if necessary, for the following variables: body weight, waist circumference, BMI, blood pressure, serum levels of 25(OH)D, blood glucose, HbA1c, insulin, IGF-1, lipids, CRP, estradiol, testosterone, SHBG, specific microRNAs, dietary glycemic index, number of steps per day and quality of life. We will also test treatment differences in medication use and medication side effects. Chi-square test will be used to compare categorical variables and Student t-test or Wilcoxon test for continuous variables. The association between each variable and prognosis will be analyzed using Cox proportional hazard model and logistic regression. Finally, we will assess whether these secondary analyses are different at year 1 compared to end of study. All statistical analyses will be conducted with SPSS statistical software version 23.0 (SPSS Inc., Chicago IL, USA).</p></sec></sec><sec id="Sec23"><title>Potential toxicity and adverse events</title><p>Toxicity due to diet, moderate exercise or vitamin D supplementation are not expected. The diet is an enhanced Mediterranean diet with one arm consuming more low GI foods and physical activity involves moderate exercise of 30&#x000a0;min of daily brisk walk and both respond to lifestyle principles suggested by cancer guidelines such as the American Cancer Society [<xref ref-type="bibr" rid="CR8">8</xref>] and the World Cancer Research Fund [<xref ref-type="bibr" rid="CR9">9</xref>]. Oral vitamin D (cholecalciferol) supplementation will be given at safe dosages (up to 4000&#x000a0;IU/day) to reach safe blood levels (60&#x000a0;ng/ml for the test arm and 30&#x000a0;ng/ml for the control arm) [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In Italy the normal range of 25(OH)D is between 30-100&#x000a0;ng/ml. Excess vitamin D levels (&#x0003e;100&#x000a0;ng/ml) could induce excess calcium absorption from the intestine and potentially result in hypercalcemia (&#x0003e;11&#x000a0;mg/dl). Both serum 25(OH)D and calcium levels are monitored throughout the study at each clinic visit and any signs or symptom of hypervitaminosis D (hypercalcemia, excess thirst, etc.) will be recorded and immediately communicated to the participant&#x02019;s physician and supplementation stopped. All adverse events occurring after signing the consent form will be recorded in a specific Adverse Event Form.</p></sec><sec id="Sec24"><title>Ethical considerations</title><p>The study will determine which group will benefit the most however both treatments are expected to gain some health benefits since both treatments are based on a healthy diet and lifestyle and sufficient vitamin D levels. An interim analysis will be conducted to evaluate whether there are excessive disadvantages for one group over the other. Should this happen the study would be terminated and both groups allowed to follow the most beneficial treatment program. Participants health complications will be dealt by the research team of doctors and by contacting patients&#x02019; physicians. Should any complication put the participant at risk by continuing the study the participant will be invited to withdraw from the study. The study participants will also have the right to withdraw from the study anytime and for any personal reason without jeopardizing their health care in the study institution or any other institution.</p></sec></sec><sec id="Sec25"><title>Discussion</title><p>The purpose of this study is to reduce BC recurrence and hence increase disease-free survival through a lifestyle program that includes a low glycemic index diet, physical activity and vitamin D supplementation in women with BC living in a Mediterranean country. It is expected that the higher intensity program of low GI diet, exercise and vitamin D will reduce BC recurrence by 50% compared to the lower intensity program.</p><p>Dietary clinical trials to reduce BC recurrence have been conducted previously. In the USA two large studies were conducted, the Women&#x02019;s Intervention Nutrition trial (WIN) and the Women&#x02019;s Healthy Eating and Living trial (WHEL). The WIN study which focused on a low-fat diet found a 24% reduction in BC recurrence after 5&#x000a0;years compared to a control of minimal dietary counselling [<xref ref-type="bibr" rid="CR10">10</xref>], whereas the WHEL study focusing on a combination of low-fat and high-fruit and -vegetable diet did not reduce BC recurrence after a 7-year intervention compared to a lower intensity fruit and vegetables advice [<xref ref-type="bibr" rid="CR11">11</xref>]. This null result may be partly explained by methodology aspects as most women had early stage BC and one of the inclusion criteria was the diagnosis of BC within 4&#x000a0;years. It is possible that such a diet may be protective if consumed earlier, possibly within 1&#x000a0;year of diagnosis as in the WIN study [<xref ref-type="bibr" rid="CR10">10</xref>]. However, in the WHEL study, women who at baseline consumed more than 3 servings of vegetables per day showed a 30% reduction in BC recurrence and an even greater reduction (up to 52%) in tamoxifen users [<xref ref-type="bibr" rid="CR55">55</xref>]. Furthermore, women who at baseline consumed at least 5 portions of vegetables/fruit per day and additionally walked for at least 30&#x000a0;min a day had a 44% higher chance of survival, independently of obesity, suggesting that obesity did not impact on lowering survival if people adhered to a healthy lifestyle pattern [<xref ref-type="bibr" rid="CR56">56</xref>]. Overall these large clinical trials suggest the importance of intervening early after diagnosis and that plant-based diets and half hour daily walk may be protective from future recurrence. The low fat advice may however be appropriate only in countries with high intakes of saturated fat. In Mediterranean countries where diets are characterized by high intakes of olive oil, reducing fat intakes may not be beneficial. In the PREDIMED intervention trial, women without BC but following the intensive Mediterranean dietary advice with high olive oil intakes showed up to 68% lower risk of BC compared with those on lower olive oil intake [<xref ref-type="bibr" rid="CR57">57</xref>]. The traditional Mediterranean diet, rich in plant food and olive oil, has been associated with protection from BC risk [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] CVD events [<xref ref-type="bibr" rid="CR60">60</xref>], type two diabetes risk [<xref ref-type="bibr" rid="CR61">61</xref>] and complications [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] and favour weight loss [<xref ref-type="bibr" rid="CR64">64</xref>]. However, adherence to a traditional Mediterranean diet has halved from the 60&#x02019;s to 2003 in Mediterranean countries including Italy [<xref ref-type="bibr" rid="CR65">65</xref>], hence there may be health benefits in improving the current Mediterranean style dietary pattern. The Italian diet is very rich in carbohydrates, particularly bread and other fast absorbing carbohydrates (high GI foods) which have been associated with higher risk of BC as well as other chronic conditions [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Since factors influencing the metabolism of glucose may play a relevant role in the development of chronic diseases including BC [<xref ref-type="bibr" rid="CR15">15</xref>], it is possible that lowering the GI of the Mediterranean diet of Italian women with BC through guided dietary advice, a lower recurrence may be achieved. Chronic elevation of insulin concentrations may be one of the mechanisms explaining the positive association between dietary GI and cancer risk [<xref ref-type="bibr" rid="CR67">67</xref>]. High GI diets increase blood glucose and insulin levels more than low GI diets and hence may be involved in increasing IGF-1 bioavailability [<xref ref-type="bibr" rid="CR31">31</xref>]. Insulin is an anabolic hormone able to increase IGF-1 synthesis and activity and IGF-1 in turn may promote cancer development by inhibiting apoptosis, stimulating cell proliferation and sex-steroid synthesis [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Another mechanism for high GI-related increased cancer risk may be through hyperglycemia-induced oxidative stress [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] which has been implicated in free radical-dependent DNA damage, known as a contributor to carcinogenesis [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Within normal ranges of glycemia higher levels of normal have been directly associated with BC risk in previously healthy women [<xref ref-type="bibr" rid="CR74">74</xref>] and with higher recurrence rates in women with BC [<xref ref-type="bibr" rid="CR75">75</xref>]. Another potential mechanism may be through lowering the availability of circulating glucose following low GI diets and exercise. Cancer cells are avid consumers of glucose due to their altered metabolism characterized by insufficient oxidative phosphorylation and compensatory glucose fermentation (the Warburg effect) [<xref ref-type="bibr" rid="CR76">76</xref>]. This results in lactic acid production and higher protons which acidify the external cellular microenvironment reaching a pH of 6.5-6.9 [<xref ref-type="bibr" rid="CR77">77</xref>]. A lower pH may provide a competing survival and metastatic advantage for cancer cells (e.g. greater spreading capacity) over normal cells unable to survive below a pH of 7.2 [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>] and may induce drug resistance of weak base-anticancer drugs (e.g. doxorubicin) [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p>Physical activity after BC diagnosis has also been shown to reduce the risk of BC mortality by 40-50% particularly when it is of moderate intensity such as 30&#x000a0;minutes of brisk walking per day [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. This effect may be modulated partly by reduced insulin, insulin-like growth factors and estrogen levels [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>] which are associated with BC recurrence and death [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Furthermore, physical activity can improve insulin sensitivity, reduce blood triglycerides, blood pressure and body fat [<xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. The lifestyle changes proposed in this study (lower dietary GI, enhanced Mediterranean diet, physical activity) may also induce weight loss which in turn may improve insulin sensitivity, IGF profile and reduce aromatase activity in adipose tissue with consequent reduction in estrogen levels [<xref ref-type="bibr" rid="CR86">86</xref>], particularly relevant in postmenopausal women [<xref ref-type="bibr" rid="CR87">87</xref>]. Although weight loss is not a goal of the DEDiCa study, participants will be allowed to lose weight in situations of overwheight or obesity should they wish to. The secondary statistical analyses will take into consideration this aspect.</p><p>Lifestyle changes may be more efficacious in a setting of vitamin D sufficiency. Vitamin D alters genes implicated in cellular growth, through upregulation of E-cadherin thereby stimulating cell differentiation and apoptosis [<xref ref-type="bibr" rid="CR39">39</xref>]. Higher serum vitamin D levels (&#x0003e;30&#x000a0;ng/ml) in BC patients have been associated with 50% less fatality rates compared to lower levels (&#x0003c;20&#x000a0;ng/ml) [<xref ref-type="bibr" rid="CR88">88</xref>]. The vitamin D dose&#x02013;response relationship for BC appears inverse and linear up to 60&#x000a0;ng/ml [<xref ref-type="bibr" rid="CR39">39</xref>]. These levels could achieve a 25% lower BC incidence and could be reached by supplementing 2000&#x02013;4000&#x000a0;IU/day [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. The upper dose recommended by the National Academy of Sciences is 4000&#x000a0;IU/day [<xref ref-type="bibr" rid="CR54">54</xref>]. The Italian guidelines for the prevention and treatment of hypovitaminosis D (SIOMMMS) indicate that in Italy this condition is present in 50% of young adults and at higher rates in older individuals [<xref ref-type="bibr" rid="CR53">53</xref>]. The updated SIOMMMS guidelines for vitamin D deficiency (25-OH-D&#x02009;&#x0003c;&#x02009;10&#x000a0;ng/ml) suggest up to 600,000 as a cumulative dose [<xref ref-type="bibr" rid="CR90">90</xref>]. In Italy the normal range for circulating 25-OH-D is set between 30&#x000a0;ng/ml and 100&#x000a0;ng/ml while toxicity levels are considered above 150&#x000a0;ng/ml [<xref ref-type="bibr" rid="CR53">53</xref>]. Vitamin D can also protect against bone loss and risk of fractures as a consequence of osteoporosis typically seen after postmenopause or after estrogen deprivation therapy used in BC treatment. Hence vitamin D supplementation may also reduce adverse skeletal effects [<xref ref-type="bibr" rid="CR53">53</xref>]. Furthermore, higher vitamin D levels have also been associated with reduced risk of developing diabetes [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Continuous improvements in survival rates will have an impact on comorbidities and quality of life of BC survivors. Co-morbid conditions have been found at higher prevalence in cancer survivors than in age-matched controls [<xref ref-type="bibr" rid="CR93">93</xref>] and in the subgroup of cancer patients presenting with two comorbidities, the most frequent combination of diseases appeared to be CVD in men and diabetes in women [<xref ref-type="bibr" rid="CR94">94</xref>]. There are downstream effects of cancer therapy (e.g. radiation and chemotherapy) causing heart, respiratory, kidney and memory problems but also of hormone suppressing therapy in BC patients [<xref ref-type="bibr" rid="CR95">95</xref>]. Compounding on this problem, cancer survivors fail to receive the same level of care for their comorbid condition compared to the general population [<xref ref-type="bibr" rid="CR96">96</xref>] and this is especially true for type two diabetes [<xref ref-type="bibr" rid="CR97">97</xref>]. Hence it may become even more relevant to implement cost-effective lifestyle risk reduction strategies. Two international cancer organizations have published lifestyle guidelines for cancer survivors, The American Cancer Society (ACS) [<xref ref-type="bibr" rid="CR8">8</xref>] and the World Cancer Research Fund (WCRF) [<xref ref-type="bibr" rid="CR9">9</xref>], however there is no agreement on a specific lifestyle program that could reduce BC recurrence and complications including recommendations on vitamin D supplementation.</p><p>DEDiCa study includes treatment components such as low GI, traditional Mediterranean foods, high dietary fiber and physical activity which have been shown to reduce risk factors for type two diabetes and CVD including HbA1c, blood glucose and lipids, and inflammatory factors [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR98">98</xref>&#x02013;<xref ref-type="bibr" rid="CR100">100</xref>].</p><p>This study will contribute to understanding the efficacy of lifestyle changes in a Mediterranean population of BC survivors with respect to several novel aspects: testing a lifestyle modification (diet and exercise) within normal vitamin D levels on disease-free survival; investigate lifestyle changes in relation to BC staging, molecular subtypes, menopausal status, body weight, CVD risk factors and events, diabetes control, new diabetes cases, quality of life, response to medication. It will also allow to understand breast carcinogenesis and the role of microRNA in BC and whether they are modulated by dietary and other lifestyle aspects. It will allow to investigate best time of treatment adherence since women will be enrolled within 12&#x000a0;months of surgery, some will have just started their cancer therapy and some will have ended.</p><p>Given the supporting evidence of important health effects and safety of the components of DEDiCa intervention we believe it is feasible and urgent to test this program in BC patients.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>25(OH)D</term><def><p>25-hydroxyvitamin D</p></def></def-item><def-item><term>AST/ALT</term><def><p>Aspartate transaminase/alanine transaminase</p></def></def-item><def-item><term>BC</term><def><p>Breast cancer</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>CVD</term><def><p>Cardiovascular disease</p></def></def-item><def-item><term>GI</term><def><p>Glycemic index</p></def></def-item><def-item><term>HbA1c</term><def><p>Hemoglobin A1c</p></def></def-item><def-item><term>HDL-C</term><def><p>High density lipoprotein cholesterol</p></def></def-item><def-item><term>HIT</term><def><p>High intensity treatment</p></def></def-item><def-item><term>IGF-1</term><def><p>Insulin-like growth factor-1</p></def></def-item><def-item><term>LDL-C</term><def><p>Low density lipoprotein cholesterol</p></def></def-item><def-item><term>LITE</term><def><p>Low intensity treatment</p></def></def-item><def-item><term>RNA</term><def><p>Ribonucleic acid</p></def></def-item><def-item><term>SHBG</term><def><p>Sex hormone binding globulin</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank Barilla Spa for providing pasta, Abiogen Pharma for providing vitamin D, and Lega Italiana per la Lotta Contro i Tumori (LILT Nazionale) Progetto Cinque Per Mille 2013 and LILT Catania for their support.</p><sec id="FPar1"><title>Funding</title><p>This trial is funded by a grant of the Italian Ministry of Health (grant no. PE-2013-02358099). The funding body will not play any role in the study.</p></sec><sec id="FPar2"><title>Availability of data and material</title><p>None declared.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>LSA, ML, AC, MG and MM contributed to the protocol and grant proposal. LSA, CWCK, DJAJ and GR contributed to the dietary aspect of the intervention program design, MP and LSA contributed to the exercise aspect of the intervention program design, DG and LSA contributed to the vitamin D aspect of the intervention program design. MDL, MR, MDA, FC, GB, FF, RR, DS, SM, GT, GC contributed to patient selection criteria. EC, LSA, MM and ML contributed to the biochemical analysis plan. AC, EV and EB were primarily involved in developing the statistical analysis plan. LSA wrote the manuscript. The manuscript was amended based on comments from all authors. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>LSA has received honoraria from the Nutrition Foundation of Italy (NFI, Milan) and from Lega Italiana per la Lotta Contro i Tumori (LILT-Catania). DG has received speaking and/or consulting fees from Abiogen Pharma, Amgen, Eli-Lilly, Janssen-Cilag, Merck and Mundipharma. MP has received research support from Amgen. GR has received research grants from Barilla Spa to his University Department and speaker and travel fees from Sanofi, Astra Zeneca and Takeda. CWCK has received research support from the Advanced Foods and Material Network, Agrifoods and Agriculture Canada, the Almond Board of California, the American Pistachio Growers, Barilla, the California Strawberry Commission, the Calorie Control Council, CIHR, the Canola Council of Canada, the Coca-Cola Company (investigator initiated, unrestricted grant), Hain Celestial, the International Tree Nut Council Nutrition Research and Education Foundation, Kellogg, Kraft, Loblaw Companies Ltd., Orafti, Pulse Canada, Saskatchewan Pulse Growers, Solae and Unilever. He has received travel funding, consultant fees and/or honoraria from Abbott Laboratories, the Almond Board of California, the American Peanut Council, the American Pistachio Growers, Barilla, Bayer, the Canola Council of Canada, the Coca-Cola Company, Danone, General Mills, the International Tree Nut Council Nutrition Research and Education Foundation, Kellogg, Loblaw Companies Ltd., the Nutrition Foundation of Italy, Oldways Preservation Trust, Orafti, Paramount Farms, the Peanut Institute, PepsiCo, Pulse Canada, Sabra Dipping Co., Saskatchewan Pulse Growers, Solae, Sun-Maid, Tate and Lyle, and Unilever. He has served on the scientific advisory board for the Almond Board of California, the International Tree Nut Council, Oldways Preservation Trust, Paramount Farms and Pulse Canada. He is a member of the International Carbohydrate Quality Consortium (ICQC), Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), is on the Clinical Practice Guidelines Expert Committee for Nutrition Therapy of the EASD and is a Director of the Toronto 3D Knowledge Synthesis and Clinical Trials foundation. DJAJ has received research grants from Saskatchewan Pulse Growers, the Agricultural Bioproducts Innovation Program through the Pulse Research Network, the Advanced Foods and Material Network, Loblaw Companies Ltd., Unilever, Barilla, the Almond Board of California, Agriculture and Agri-food Canada, Pulse Canada, Kellogg&#x02019;s Company, Canada, Quaker Oats, Canada, Procter &#x00026; Gamble Technical Centre Ltd., Bayer Consumer Care, Springfield, NJ, Pepsi/Quaker, International Nut &#x00026; Dried Fruit (INC), Soy Foods Association of North America, the Coca-Cola Company (investigator initiated, unrestricted grant), Solae, Haine Celestial, the Sanitarium Company, Orafti, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, the Canola and Flax Councils of Canada, the Calorie Control Council (CCC), the CIHR, the Canada Foundation for Innovation and the Ontario Research Fund. He has been on the speaker&#x02019;s panel, served on the scientific advisory board and/or received travel support and/or honoraria from the Almond Board of California, Canadian Agriculture Policy Institute, Loblaw Companies Ltd, the Griffin Hospital (for the development of the NuVal scoring system, the Coca-Cola Company, EPICURE, Danone, Saskatchewan Pulse Growers, Sanitarium Company, Orafti, the Almond Board of California, the American Peanut Council, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, Herbalife International, Pacific Health Laboratories, Nutritional Fundamental for Health, Barilla, Metagenics, Bayer Consumer Care, Unilever Canada and Netherlands, Solae, Kellogg, Quaker Oats, Procter &#x00026; Gamble, the Coca-Cola Company, the Griffin Hospital, Abbott Laboratories, the Canola Council of Canada, Dean Foods, the California Strawberry Commission, Haine Celestial, PepsiCo, the Alpro Foundation, Pioneer Hi-Bred International, DuPont Nutrition and Health, Spherix Consulting and WhiteWave Foods, the Advanced Foods and Material Network, the Canola and Flax Councils of Canada, the Nutritional Fundamentals for Health, Agri-Culture and Agri-Food Canada, the Canadian Agri-Food Policy Institute, Pulse Canada, the Saskatchewan Pulse Growers, the Soy Foods Association of North America, the Nutrition Foundation of Italy (NFI), Nutra-Source Diagnostics, the McDougall Program, the Toronto Knowledge Translation Group (St. Michael&#x02019;s Hospital), the Canadian College of Naturopathic Medicine, The Hospital for Sick Children, the Canadian Nutrition Society (CNS), the American Society of Nutrition (ASN), Arizona State University, Paolo Sorbini Foundation and the Institute of Nutrition, Metabolism and Diabetes. He received an honorarium from the US Department of Agriculture to present the 2013&#x000a0;W.O. Atwater Memorial Lecture. He received the 2013 Award for Excellence in Research from the International Nut and Dried Fruit Council. He received funding and travel support from the Canadian Society of Endocrinology and Metabolism to produce mini cases for the Canadian Diabetes Association (CDA). He is a member of the International Carbohydrate Quality Consortium (ICQC). His wife is a director and partner of Glycemic Index Laboratories, Inc., and his sister received funding through a grant from the St. Michael&#x02019;s Hospital Foundation to develop a cookbook for one of his studies. All other authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>This study was approved by the ethic board of: the Italian Medicine Agency (AIFA), the National Cancer Institute &#x0201c;Fondazione Giovanni Pascale&#x0201d; in Naples, Azienda Ospedaliera per L&#x02019;Emergenza Ospedale Cannizzaro in Catania, Azienda Ospedaliera Universitaria Policlinico &#x0201c;G. Martino&#x0201d; in Messina for San Vincenzo Hospital of Taormina, Comitato Etico Campania Centro ASL NA1 Centro for Clinica Mediterranea in Naples. Written informed consent will be obtained from each recruited patient before the intervention and questionnaire survey.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Angelis</surname><given-names>R</given-names></name><name><surname>Sant</surname><given-names>M</given-names></name><name><surname>Coleman</surname><given-names>MP</given-names></name><name><surname>Francisci</surname><given-names>S</given-names></name><name><surname>Baili</surname><given-names>P</given-names></name><name><surname>Pierannunzio</surname><given-names>D</given-names></name><name><surname>Trama</surname><given-names>A</given-names></name><name><surname>Visser</surname><given-names>O</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Ardanaz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cancer survival in Europe 1999&#x02013;2007 by country and age: results of EUROCARE--5-a population-based study</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70546-1</pub-id><pub-id pub-id-type="pmid">24314615</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>FJ</given-names></name><name><surname>Liu</surname><given-names>ZB</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>GY</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><article-title>Impact of type two diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People&#x02019;s Republic of China</article-title><source>OncoTargets Ther</source><year>2014</year><volume>7</volume><fpage>2147</fpage><lpage>2154</lpage><pub-id pub-id-type="doi">10.2147/OTT.S71095</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>MA</given-names></name><name><surname>Pekkolay</surname><given-names>Z</given-names></name><name><surname>Kucukoner</surname><given-names>M</given-names></name><name><surname>Inal</surname><given-names>A</given-names></name><name><surname>Urakci</surname><given-names>Z</given-names></name><name><surname>Ertugrul</surname><given-names>H</given-names></name><name><surname>Akdogan</surname><given-names>R</given-names></name><name><surname>Firat</surname><given-names>U</given-names></name><name><surname>Yildiz</surname><given-names>I</given-names></name><name><surname>Isikdogan</surname><given-names>A</given-names></name></person-group><article-title>Type two diabetes mellitus and prognosis in early stage breast cancer women</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><issue>3</issue><fpage>1576</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1007/s12032-011-0109-4</pub-id><pub-id pub-id-type="pmid">22083554</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas-Martinez</surname><given-names>AM</given-names></name><name><surname>Flores-Cortes</surname><given-names>LI</given-names></name><name><surname>Cardona-Chavarria</surname><given-names>JM</given-names></name><name><surname>Hernandez-Gutierrez</surname><given-names>B</given-names></name><name><surname>Abundis</surname><given-names>A</given-names></name><name><surname>Vazquez-Lara</surname><given-names>J</given-names></name><name><surname>Gonzalez-Guajardo</surname><given-names>EE</given-names></name></person-group><article-title>Prediabetes, diabetes, and risk of breast cancer: a case&#x02013;control study</article-title><source>Arch Med Res</source><year>2014</year><volume>45</volume><issue>5</issue><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2014.06.004</pub-id><pub-id pub-id-type="pmid">24937172</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armenian</surname><given-names>SH</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Ky</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Farol</surname><given-names>LT</given-names></name><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name></person-group><article-title>Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>10</issue><fpage>1122</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.0409</pub-id><pub-id pub-id-type="pmid">26834065</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Gavila J, Segu&#x000ed; M&#x000c1;, Calvo L, L&#x000f3;pez T, Alonso JJ, Farto M, S&#x000e1;nchez-de la Rosa R. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clin Transl Oncol. 2017;19(1):91&#x02013;104. doi:10.1007/s12094-016-1508-y.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Harlan</surname><given-names>DM</given-names></name><name><surname>Archer</surname><given-names>MC</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Gapstur</surname><given-names>SM</given-names></name><name><surname>Habel</surname><given-names>LA</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Regensteiner</surname><given-names>JG</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name></person-group><article-title>Diabetes and cancer: a consensus report</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>7</issue><fpage>1674</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.2337/dc10-0666</pub-id><pub-id pub-id-type="pmid">20587728</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>CL</given-names></name><name><surname>Doyle</surname><given-names>C</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Meyerhardt</surname><given-names>J</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Schwartz</surname><given-names>AL</given-names></name><name><surname>Bandera</surname><given-names>EV</given-names></name><name><surname>Hamilton</surname><given-names>KK</given-names></name><name><surname>Grant</surname><given-names>B</given-names></name><name><surname>McCullough</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nutrition and physical activity guidelines for cancer survivors</article-title><source>CA Cancer J Clin</source><year>2012</year><volume>62</volume><issue>4</issue><fpage>243</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.3322/caac.21142</pub-id><pub-id pub-id-type="pmid">22539238</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">WCRF. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.wcrf.org/int/cancer-facts-figures/worldwide-data">http://www.wcrf.org/int/cancer-facts-figures/worldwide-data</ext-link> Accessed 22 January 2016.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chlebowski</surname><given-names>RT</given-names></name><name><surname>Blackburn</surname><given-names>GL</given-names></name><name><surname>Thomson</surname><given-names>CA</given-names></name><name><surname>Nixon</surname><given-names>DW</given-names></name><name><surname>Shapiro</surname><given-names>A</given-names></name><name><surname>Hoy</surname><given-names>MK</given-names></name><name><surname>Goodman</surname><given-names>MT</given-names></name><name><surname>Giuliano</surname><given-names>AE</given-names></name><name><surname>Karanja</surname><given-names>N</given-names></name><name><surname>McAndrew</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women&#x02019;s intervention nutrition study</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><issue>24</issue><fpage>1767</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1093/jnci/djj494</pub-id><pub-id pub-id-type="pmid">17179478</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women&#x02019;s healthy eating and living (WHEL) randomized trial. JAMA. 2007;298(3):289&#x02013;98.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushi</surname><given-names>LH</given-names></name><name><surname>Kwan</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>MM</given-names></name><name><surname>Ambrosone</surname><given-names>CB</given-names></name></person-group><article-title>Lifestyle factors and survival in women with breast cancer</article-title><source>J Nutr</source><year>2007</year><volume>137</volume><issue>1 Suppl</issue><fpage>236S</fpage><lpage>242S</lpage><pub-id pub-id-type="pmid">17182833</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runowicz</surname><given-names>CD</given-names></name><name><surname>Leach</surname><given-names>CR</given-names></name><name><surname>Henry</surname><given-names>NL</given-names></name><name><surname>Henry</surname><given-names>KS</given-names></name><name><surname>Mackey</surname><given-names>HT</given-names></name><name><surname>Cowens-Alvarado</surname><given-names>RL</given-names></name><name><surname>Cannady</surname><given-names>RS</given-names></name><name><surname>Pratt-Chapman</surname><given-names>ML</given-names></name><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Jacobs</surname><given-names>LA</given-names></name><etal/></person-group><article-title>American cancer society/american society of clinical oncology breast cancer survivorship care guideline</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>6</issue><fpage>611</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.3809</pub-id><pub-id pub-id-type="pmid">26644543</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Wolever</surname><given-names>TM</given-names></name><name><surname>Taylor</surname><given-names>RH</given-names></name><name><surname>Barker</surname><given-names>H</given-names></name><name><surname>Fielden</surname><given-names>H</given-names></name><name><surname>Baldwin</surname><given-names>JM</given-names></name><name><surname>Bowling</surname><given-names>AC</given-names></name><name><surname>Newman</surname><given-names>HC</given-names></name><name><surname>Jenkins</surname><given-names>AL</given-names></name><name><surname>Goff</surname><given-names>DV</given-names></name></person-group><article-title>Glycemic index of foods: a physiological basis for carbohydrate exchange</article-title><source>Am J Clin Nutr</source><year>1981</year><volume>34</volume><issue>3</issue><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">6259925</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barclay</surname><given-names>AW</given-names></name><name><surname>Petocz</surname><given-names>P</given-names></name><name><surname>McMillan-Price</surname><given-names>J</given-names></name><name><surname>Flood</surname><given-names>VM</given-names></name><name><surname>Prvan</surname><given-names>T</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Brand-Miller</surname><given-names>JC</given-names></name></person-group><article-title>Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><issue>3</issue><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">18326601</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turati</surname><given-names>F</given-names></name><name><surname>Galeone</surname><given-names>C</given-names></name><name><surname>Gandini</surname><given-names>S</given-names></name><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Pelucchi</surname><given-names>C</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>High glycemic index and glycemic load are associated with moderately increased cancer risk</article-title><source>Mol Nutr Food Res</source><year>2015</year><volume>59</volume><issue>7</issue><fpage>1384</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201400594</pub-id><pub-id pub-id-type="pmid">25693843</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name></person-group><article-title>Glycaemic index and glycaemic load in relation to risk of diabetes-related cancers: a meta-analysis</article-title><source>Br J Nutr</source><year>2012</year><volume>108</volume><issue>11</issue><fpage>1934</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1017/S0007114512003984</pub-id><pub-id pub-id-type="pmid">23167978</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Dal Maso</surname><given-names>L</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Parpinel</surname><given-names>M</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><name><surname>Vaccarella</surname><given-names>S</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Francesch</surname><given-names>S</given-names></name></person-group><article-title>Dietary glycemic index and glycemic load, and breast cancer risk: a case&#x02013;control study</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><issue>11</issue><fpage>1533</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1023/A:1013176129380</pub-id><pub-id pub-id-type="pmid">11822751</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyerhardt</surname><given-names>JA</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Niedzwiecki</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Mayer</surname><given-names>RJ</given-names></name><name><surname>Mowat</surname><given-names>RB</given-names></name><name><surname>Whittom</surname><given-names>R</given-names></name><name><surname>Hantel</surname><given-names>A</given-names></name><name><surname>Benson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><issue>22</issue><fpage>1702</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs399</pub-id><pub-id pub-id-type="pmid">23136358</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livesey</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Livesey</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Is there a dose&#x02013;response relation of dietary glycemic load to risk of type two diabetes? meta-analysis of prospective cohort studies</article-title><source>Am J Clin Nutr</source><year>2013</year><volume>97</volume><issue>3</issue><fpage>584</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.041467</pub-id><pub-id pub-id-type="pmid">23364021</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhupathiraju</surname><given-names>SN</given-names></name><name><surname>Tobias</surname><given-names>DK</given-names></name><name><surname>Malik</surname><given-names>VS</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Hruby</surname><given-names>A</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name></person-group><article-title>Glycemic index, glycemic load, and risk of type two diabetes: results from three large US cohorts and an updated meta-analysis</article-title><source>Am J Clin Nutr</source><year>2014</year><volume>100</volume><issue>1</issue><fpage>218</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.3945/ajcn.113.079533</pub-id><pub-id pub-id-type="pmid">24787496</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Dietary glycemic index, glycemic load, and risk of coronary heart disease, stroke, and stroke mortality: a systematic review with meta-analysis</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>12</issue><fpage>e52182</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0052182</pub-id><pub-id pub-id-type="pmid">23284926</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirrahimi</surname><given-names>A</given-names></name><name><surname>de Souza</surname><given-names>RJ</given-names></name><name><surname>Chiavaroli</surname><given-names>L</given-names></name><name><surname>Sievenpiper</surname><given-names>JL</given-names></name><name><surname>Beyene</surname><given-names>J</given-names></name><name><surname>Hanley</surname><given-names>AJ</given-names></name><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>Jenkins</surname><given-names>DJ</given-names></name></person-group><article-title>Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts</article-title><source>J Am Heart Assoc</source><year>2012</year><volume>1</volume><issue>5</issue><fpage>e000752</fpage><pub-id pub-id-type="doi">10.1161/JAHA.112.000752</pub-id><pub-id pub-id-type="pmid">23316283</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>McKeown-Eyssen</surname><given-names>G</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Silverberg</surname><given-names>J</given-names></name><name><surname>Booth</surname><given-names>GL</given-names></name><name><surname>Vidgen</surname><given-names>E</given-names></name><name><surname>Josse</surname><given-names>AR</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Corrigan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of a low-glycemic index or a high-cereal fiber diet on type two diabetes: a randomized trial</article-title><source>JAMA</source><year>2008</year><volume>300</volume><issue>23</issue><fpage>2742</fpage><lpage>2753</lpage><pub-id pub-id-type="doi">10.1001/jama.2008.808</pub-id><pub-id pub-id-type="pmid">19088352</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand-Miller</surname><given-names>J</given-names></name><name><surname>Hayne</surname><given-names>S</given-names></name><name><surname>Petocz</surname><given-names>P</given-names></name><name><surname>Colagiuri</surname><given-names>S</given-names></name></person-group><article-title>Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>8</issue><fpage>2261</fpage><lpage>2267</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.8.2261</pub-id><pub-id pub-id-type="pmid">12882846</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Mitchell</surname><given-names>S</given-names></name><name><surname>Sahye-Pudaruth</surname><given-names>S</given-names></name><name><surname>Blanco Mejia</surname><given-names>S</given-names></name><name><surname>Chiavaroli</surname><given-names>L</given-names></name><name><surname>Mirrahimi</surname><given-names>A</given-names></name><name><surname>Ireland</surname><given-names>C</given-names></name><name><surname>Bashyam</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type two diabetes mellitus: a randomized controlled trial</article-title><source>Arch Intern Med</source><year>2012</year><volume>172</volume><issue>21</issue><fpage>1653</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1001/2013.jamainternmed.70</pub-id><pub-id pub-id-type="pmid">23089999</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goff</surname><given-names>LM</given-names></name><name><surname>Cowland</surname><given-names>DE</given-names></name><name><surname>Hooper</surname><given-names>L</given-names></name><name><surname>Frost</surname><given-names>GS</given-names></name></person-group><article-title>Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2013</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2012.06.002</pub-id><pub-id pub-id-type="pmid">22841185</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolever</surname><given-names>TM</given-names></name><name><surname>Gibbs</surname><given-names>AL</given-names></name><name><surname>Mehling</surname><given-names>C</given-names></name><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Connelly</surname><given-names>PW</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Leiter</surname><given-names>LA</given-names></name><name><surname>Maheux</surname><given-names>P</given-names></name><name><surname>Rabasa-Lhoret</surname><given-names>R</given-names></name><name><surname>Rodger</surname><given-names>NW</given-names></name><etal/></person-group><article-title>The canadian trial of carbohydrates in diabetes (ccd), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type two diabetes: no effect on glycated hemoglobin but reduction in c-reactive protein</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><issue>1</issue><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">18175744</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botero</surname><given-names>D</given-names></name><name><surname>Ebbeling</surname><given-names>CB</given-names></name><name><surname>Blumberg</surname><given-names>JB</given-names></name><name><surname>Ribaya-Mercado</surname><given-names>JD</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Swain</surname><given-names>JF</given-names></name><name><surname>Feldman</surname><given-names>HA</given-names></name><name><surname>Ludwig</surname><given-names>DS</given-names></name></person-group><article-title>Acute effects of dietary glycemic index on antioxidant capacity in a nutrient-controlled feeding study</article-title><source>Obesity (Silver Spring)</source><year>2009</year><volume>17</volume><issue>9</issue><fpage>1664</fpage><lpage>1670</lpage><pub-id pub-id-type="doi">10.1038/oby.2009.203</pub-id><pub-id pub-id-type="pmid">19543205</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>TM</given-names></name><name><surname>Dalskov</surname><given-names>SM</given-names></name><name><surname>van Baak</surname><given-names>M</given-names></name><name><surname>Jebb</surname><given-names>SA</given-names></name><name><surname>Papadaki</surname><given-names>A</given-names></name><name><surname>Pfeiffer</surname><given-names>AF</given-names></name><name><surname>Martinez</surname><given-names>JA</given-names></name><name><surname>Handjieva-Darlenska</surname><given-names>T</given-names></name><name><surname>Kunesova</surname><given-names>M</given-names></name><name><surname>Pihlsgard</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diets with high or low protein content and glycemic index for weight-loss maintenance</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>22</issue><fpage>2102</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1007137</pub-id><pub-id pub-id-type="pmid">21105792</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand-Miller</surname><given-names>JC</given-names></name><name><surname>Liu</surname><given-names>V</given-names></name><name><surname>Petocz</surname><given-names>P</given-names></name><name><surname>Baxter</surname><given-names>RC</given-names></name></person-group><article-title>The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>82</volume><issue>2</issue><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">16087978</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>EM</given-names></name><name><surname>Al-Homaidh</surname><given-names>A</given-names></name></person-group><article-title>Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies</article-title><source>Med Oncol</source><year>2011</year><volume>28</volume><issue>3</issue><fpage>753</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1007/s12032-010-9536-x</pub-id><pub-id pub-id-type="pmid">20411366</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>CN</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Trentham-Dietz</surname><given-names>A</given-names></name><name><surname>Titus-Ernstoff</surname><given-names>L</given-names></name><name><surname>Bersch</surname><given-names>AJ</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Baron</surname><given-names>JA</given-names></name><name><surname>Egan</surname><given-names>KM</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name></person-group><article-title>Physical activity and survival after diagnosis of invasive breast cancer</article-title><source>Cancer Epidem Biomar Prev</source><year>2008</year><volume>17</volume><issue>2</issue><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0771</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard-Barbash</surname><given-names>R</given-names></name><name><surname>Friedenreich</surname><given-names>CM</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Siddiqi</surname><given-names>SM</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><name><surname>Alfano</surname><given-names>CM</given-names></name></person-group><article-title>Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><issue>11</issue><fpage>815</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs207</pub-id><pub-id pub-id-type="pmid">22570317</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Feskanich</surname><given-names>D</given-names></name><name><surname>Kroenke</surname><given-names>CH</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name></person-group><article-title>Physical activity and survival after breast cancer diagnosis</article-title><source>JAMA</source><year>2005</year><volume>293</volume><issue>20</issue><fpage>2479</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1001/jama.293.20.2479</pub-id><pub-id pub-id-type="pmid">15914748</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligibel</surname><given-names>JA</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><name><surname>Partridge</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Salinardi</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Adloff</surname><given-names>K</given-names></name><name><surname>Keshaviah</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name></person-group><article-title>Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>6</issue><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.7357</pub-id><pub-id pub-id-type="pmid">18281663</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>D</given-names></name><name><surname>Krishnan</surname><given-names>AV</given-names></name><name><surname>Swami</surname><given-names>S</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Feldman</surname><given-names>BJ</given-names></name></person-group><article-title>The role of vitamin D in reducing cancer risk and progression</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><issue>5</issue><fpage>342</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nrc3691</pub-id><pub-id pub-id-type="pmid">24705652</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannucci</surname><given-names>E</given-names></name></person-group><article-title>Vitamin D and cancer incidence in the Harvard cohorts</article-title><source>Ann Epidemiol</source><year>2009</year><volume>19</volume><issue>2</issue><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2007.12.002</pub-id><pub-id pub-id-type="pmid">18291673</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>CF</given-names></name><name><surname>Gorham</surname><given-names>ED</given-names></name><name><surname>Mohr</surname><given-names>SB</given-names></name><name><surname>Garland</surname><given-names>FC</given-names></name></person-group><article-title>Vitamin D for cancer prevention: global perspective</article-title><source>Ann Epidemiol</source><year>2009</year><volume>19</volume><issue>7</issue><fpage>468</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2009.03.021</pub-id><pub-id pub-id-type="pmid">19523595</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lappe</surname><given-names>JM</given-names></name><name><surname>Travers-Gustafson</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>KM</given-names></name><name><surname>Recker</surname><given-names>RR</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name></person-group><article-title>Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>85</volume><issue>6</issue><fpage>1586</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">17556697</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>SE</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Hong</surname><given-names>CC</given-names></name><name><surname>Newman</surname><given-names>VA</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>Reduction of dietary glycaemic load modifies the expression of microRNA potentially associated with energy balance and cancer pathways in pre-menopausal women</article-title><source>Br J Nutr</source><year>2013</year><volume>109</volume><issue>4</issue><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1017/S0007114512001936</pub-id><pub-id pub-id-type="pmid">22647265</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntanasis-Stathopoulos</surname><given-names>J</given-names></name><name><surname>Tzanninis</surname><given-names>JG</given-names></name><name><surname>Philippou</surname><given-names>A</given-names></name><name><surname>Koutsilieris</surname><given-names>M</given-names></name></person-group><article-title>Epigenetic regulation on gene expression induced by physical exercise</article-title><source>J Musculoskelet Neuronal Interact</source><year>2013</year><volume>13</volume><issue>2</issue><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">23728100</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giangreco</surname><given-names>AA</given-names></name><name><surname>Nonn</surname><given-names>L</given-names></name></person-group><article-title>The sum of many small changes: microRNAs are specifically and potentially globally altered by vitamin D3 metabolites</article-title><source>J Steroid Biochem Mol Biol</source><year>2013</year><volume>136</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2013.01.001</pub-id><pub-id pub-id-type="pmid">23333596</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordero</surname><given-names>F</given-names></name><name><surname>Ferrero</surname><given-names>G</given-names></name><name><surname>Polidoro</surname><given-names>S</given-names></name><name><surname>Fiorito</surname><given-names>G</given-names></name><name><surname>Campanella</surname><given-names>G</given-names></name><name><surname>Sacerdote</surname><given-names>C</given-names></name><name><surname>Mattiello</surname><given-names>A</given-names></name><name><surname>Masala</surname><given-names>G</given-names></name><name><surname>Agnoli</surname><given-names>C</given-names></name><name><surname>Frasca</surname><given-names>G</given-names></name><etal/></person-group><article-title>Differentially methylated micrornas in prediagnostic samples of subjects who developed breast cancer in the european prospective investigation into nutrition and cancer (epic-italy) cohort</article-title><source>Carcinogenesis</source><year>2015</year><volume>36</volume><issue>10</issue><fpage>1144</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgv102</pub-id><pub-id pub-id-type="pmid">26168820</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulyaeva</surname><given-names>LF</given-names></name><name><surname>Kushlinskiy</surname><given-names>NE</given-names></name></person-group><article-title>Regulatory mechanisms of microRNA expression</article-title><source>J Transl Med</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/s12967-016-0893-x</pub-id><pub-id pub-id-type="pmid">27197967</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Khanbashi</surname><given-names>M</given-names></name><name><surname>Caramuta</surname><given-names>S</given-names></name><name><surname>Alajmi</surname><given-names>AM</given-names></name><name><surname>Al-Haddabi</surname><given-names>I</given-names></name><name><surname>Al-Riyami</surname><given-names>M</given-names></name><name><surname>Lui</surname><given-names>WO</given-names></name><name><surname>Al-Moundhri</surname><given-names>MS</given-names></name></person-group><article-title>Tissue and serum mirna profile in locally advanced breast cancer (labc) in response to neo-adjuvant chemotherapy (nac) treatment</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>4</issue><fpage>e0152032</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0152032</pub-id><pub-id pub-id-type="pmid">27064979</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EuroQol</surname><given-names>G</given-names></name></person-group><article-title>EuroQol--a new facility for the measurement of health-related quality of life</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><issue>3</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id><pub-id pub-id-type="pmid">10109801</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fayers</surname><given-names>PM</given-names></name></person-group><article-title>Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><issue>11</issue><fpage>1331</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00127-7</pub-id><pub-id pub-id-type="pmid">11435060</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprangers</surname><given-names>MA</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>Arraras</surname><given-names>JI</given-names></name><name><surname>Franklin</surname><given-names>J</given-names></name><name><surname>te Velde</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Franzini</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>de Haes</surname><given-names>HC</given-names></name><name><surname>Hopwood</surname><given-names>P</given-names></name><etal/></person-group><article-title>The european organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><issue>10</issue><fpage>2756</fpage><lpage>2768</lpage><pub-id pub-id-type="pmid">8874337</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuk</surname><given-names>K</given-names></name><name><surname>Zucknick</surname><given-names>M</given-names></name><name><surname>Madhavan</surname><given-names>D</given-names></name><name><surname>Schott</surname><given-names>S</given-names></name><name><surname>Golatta</surname><given-names>M</given-names></name><name><surname>Heil</surname><given-names>J</given-names></name><name><surname>Marme</surname><given-names>F</given-names></name><name><surname>Turchinovich</surname><given-names>A</given-names></name><name><surname>Sinn</surname><given-names>P</given-names></name><name><surname>Sohn</surname><given-names>C</given-names></name><etal/></person-group><article-title>Plasma microRNA panel for minimally invasive detection of breast cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>10</issue><fpage>e76729</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0076729</pub-id><pub-id pub-id-type="pmid">24194846</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutar</surname><given-names>Y</given-names></name></person-group><article-title>miRNA and cancer; computational and experimental approaches</article-title><source>Curr Pharm Biotechnol</source><year>2014</year><volume>15</volume><issue>5</issue><fpage>429</fpage><pub-id pub-id-type="doi">10.2174/138920101505140828161335</pub-id><pub-id pub-id-type="pmid">25189575</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>S</given-names></name><name><surname>Pappalardo</surname><given-names>F</given-names></name></person-group><article-title>Mathematical modeling of biological systems</article-title><source>Brief Bioinform</source><year>2013</year><volume>14</volume><issue>4</issue><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs061</pub-id><pub-id pub-id-type="pmid">23063928</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adami</surname><given-names>S</given-names></name><name><surname>Romagnoli</surname><given-names>E</given-names></name><name><surname>Carnevale</surname><given-names>V</given-names></name><name><surname>Scillitani</surname><given-names>A</given-names></name><name><surname>Giusti</surname><given-names>A</given-names></name><name><surname>Rossini</surname><given-names>M</given-names></name><name><surname>Gatti</surname><given-names>D</given-names></name><name><surname>Nuti</surname><given-names>R</given-names></name><name><surname>Minisola</surname><given-names>S</given-names></name><collab>Italian Society for Osteoporosis, Mineral Metabolism</collab><etal/></person-group><article-title>Guidelines on prevention and treatment of vitamin d deficiency. Italian society for osteoporosis, Imineral metabolism and bone diseases (siommms)</article-title><source>Reumatismo</source><year>2011</year><volume>63</volume><issue>3</issue><fpage>129</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.4081/reumatismo.2011.129</pub-id><pub-id pub-id-type="pmid">22257914</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>AC</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Abrams</surname><given-names>SA</given-names></name><name><surname>Aloia</surname><given-names>JF</given-names></name><name><surname>Brannon</surname><given-names>PM</given-names></name><name><surname>Clinton</surname><given-names>SK</given-names></name><name><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name><name><surname>Gallagher</surname><given-names>JC</given-names></name><name><surname>Gallo</surname><given-names>RL</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><etal/></person-group><article-title>The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><issue>1</issue><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-2704</pub-id><pub-id pub-id-type="pmid">21118827</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>CA</given-names></name><name><surname>Rock</surname><given-names>CL</given-names></name><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><name><surname>Cussler</surname><given-names>E</given-names></name><name><surname>Flatt</surname><given-names>SW</given-names></name><name><surname>Pierce</surname><given-names>JP</given-names></name></person-group><article-title>Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the women&#x02019;s healthy eating and living study</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>125</volume><issue>2</issue><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-1014-9</pub-id><pub-id pub-id-type="pmid">20607600</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JP</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Flatt</surname><given-names>SW</given-names></name><name><surname>Natarajan</surname><given-names>L</given-names></name><name><surname>Sternfeld</surname><given-names>B</given-names></name><name><surname>Madlensky</surname><given-names>L</given-names></name><name><surname>Al-Delaimy</surname><given-names>WK</given-names></name><name><surname>Thomson</surname><given-names>CA</given-names></name><name><surname>Kealey</surname><given-names>S</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><etal/></person-group><article-title>Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>17</issue><fpage>2345</fpage><lpage>2351</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.6819</pub-id><pub-id pub-id-type="pmid">17557947</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>E</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name><name><surname>Donat-Vargas</surname><given-names>C</given-names></name><name><surname>Buil-Cosiales</surname><given-names>P</given-names></name><name><surname>Estruch</surname><given-names>R</given-names></name><name><surname>Ros</surname><given-names>E</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Fito</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Aros</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the predimed trial: a randomized clinical trial</article-title><source>JAMA Intern Med</source><year>2015</year><volume>175</volume><issue>11</issue><fpage>1752</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.4838</pub-id><pub-id pub-id-type="pmid">26365989</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckland</surname><given-names>G</given-names></name><name><surname>Travier</surname><given-names>N</given-names></name><name><surname>Cottet</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>CA</given-names></name><name><surname>Lujan-Barroso</surname><given-names>L</given-names></name><name><surname>Agudo</surname><given-names>A</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Lagiou</surname><given-names>P</given-names></name><name><surname>Trichopoulos</surname><given-names>D</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study</article-title><source>Int J Cancer</source><year>2013</year><volume>132</volume><issue>12</issue><fpage>2918</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1002/ijc.27958</pub-id><pub-id pub-id-type="pmid">23180513</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>la Vecchia</surname><given-names>C</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Decarli</surname><given-names>A</given-names></name><name><surname>Giacosa</surname><given-names>A</given-names></name><name><surname>Lipworth</surname><given-names>L</given-names></name></person-group><article-title>Olive oil, other dietary fats, and the risk of breast cancer (Italy)</article-title><source>Cancer Causes Contr</source><year>1995</year><volume>6</volume><issue>6</issue><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1007/BF00054164</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estruch</surname><given-names>R</given-names></name><name><surname>Ros</surname><given-names>E</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name><name><surname>Covas</surname><given-names>MI</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Aros</surname><given-names>F</given-names></name><name><surname>Gomez-Gracia</surname><given-names>E</given-names></name><name><surname>Ruiz-Gutierrez</surname><given-names>V</given-names></name><name><surname>Fiol</surname><given-names>M</given-names></name><name><surname>Lapetra</surname><given-names>J</given-names></name><etal/></person-group><article-title>Primary prevention of cardiovascular disease with a Mediterranean diet</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>14</issue><fpage>1279</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200303</pub-id><pub-id pub-id-type="pmid">23432189</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwingshackl</surname><given-names>L</given-names></name><name><surname>Missbach</surname><given-names>B</given-names></name><name><surname>Konig</surname><given-names>J</given-names></name><name><surname>Hoffmann</surname><given-names>G</given-names></name></person-group><article-title>Adherence to a Mediterranean diet and risk of diabetes: a systematic review and meta-analysis</article-title><source>Public Health Nutr</source><year>2015</year><volume>18</volume><issue>7</issue><fpage>1292</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1017/S1368980014001542</pub-id><pub-id pub-id-type="pmid">25145972</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajala</surname><given-names>O</given-names></name><name><surname>English</surname><given-names>P</given-names></name><name><surname>Pinkney</surname><given-names>J</given-names></name></person-group><article-title>Systematic review and meta-analysis of different dietary approaches to the management of type two diabetes</article-title><source>Am J Clin Nutr</source><year>2013</year><volume>97</volume><issue>3</issue><fpage>505</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.042457</pub-id><pub-id pub-id-type="pmid">23364002</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Maiorino</surname><given-names>MI</given-names></name><name><surname>Bellastella</surname><given-names>G</given-names></name><name><surname>Chiodini</surname><given-names>P</given-names></name><name><surname>Panagiotakos</surname><given-names>D</given-names></name><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group><article-title>A journey into a Mediterranean diet and type two diabetes: a systematic review with meta-analyses</article-title><source>BMJ Open</source><year>2015</year><volume>5</volume><issue>8</issue><fpage>e008222</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2015-008222</pub-id><pub-id pub-id-type="pmid">26260349</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasa</surname><given-names>A</given-names></name><name><surname>Miranda</surname><given-names>J</given-names></name><name><surname>Bullo</surname><given-names>M</given-names></name><name><surname>Casas</surname><given-names>R</given-names></name><name><surname>Salas-Salvado</surname><given-names>J</given-names></name><name><surname>Larretxi</surname><given-names>I</given-names></name><name><surname>Estruch</surname><given-names>R</given-names></name><name><surname>Ruiz-Gutierrez</surname><given-names>V</given-names></name><name><surname>Portillo</surname><given-names>MP</given-names></name></person-group><article-title>Comparative effect of two mediterranean diets versus a low-fat diet on glycaemic control in individuals with type two diabetes</article-title><source>Eur J Clin Nutr</source><year>2014</year><volume>68</volume><issue>7</issue><fpage>767</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1038/ejcn.2014.1</pub-id><pub-id pub-id-type="pmid">24518752</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>R</given-names></name><name><surname>Bach-Faig</surname><given-names>A</given-names></name><name><surname>Raido Quintana</surname><given-names>B</given-names></name><name><surname>Buckland</surname><given-names>G</given-names></name><name><surname>Vaz de Almeida</surname><given-names>MD</given-names></name><name><surname>Serra-Majem</surname><given-names>L</given-names></name></person-group><article-title>Worldwide variation of adherence to the Mediterranean diet, in 1961&#x02013;1965 and 2000&#x02013;2003</article-title><source>Public Health Nutr</source><year>2009</year><volume>12</volume><issue>9A</issue><fpage>1676</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1017/S1368980009990541</pub-id><pub-id pub-id-type="pmid">19689839</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Malerba</surname><given-names>S</given-names></name><name><surname>Lugo</surname><given-names>A</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Talamini</surname><given-names>R</given-names></name><name><surname>Serraino</surname><given-names>D</given-names></name><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>Associations of bread and pasta with the risk of cancer of the breast and colorectum</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>12</issue><fpage>3094</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt383</pub-id><pub-id pub-id-type="pmid">24155133</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>Glycemic index in chronic disease: a review</article-title><source>Eur J Clin Nutr</source><year>2002</year><volume>56</volume><issue>11</issue><fpage>1049</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1601454</pub-id><pub-id pub-id-type="pmid">12428171</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renehan</surname><given-names>AG</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name><name><surname>O&#x02019;Dwyer</surname><given-names>ST</given-names></name><name><surname>Shalet</surname><given-names>SM</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name></person-group><article-title>Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis</article-title><source>Lancet</source><year>2004</year><volume>363</volume><issue>9418</issue><fpage>1346</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16044-3</pub-id><pub-id pub-id-type="pmid">15110491</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Lukanova</surname><given-names>A</given-names></name></person-group><article-title>Energy balance and cancer: the role of insulin and insulin-like growth factor-I</article-title><source>Proc Nutr Soc</source><year>2001</year><volume>60</volume><issue>1</issue><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1079/PNS200070</pub-id><pub-id pub-id-type="pmid">11310428</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><article-title>The pathobiology of diabetic complications: a unifying mechanism</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><issue>6</issue><fpage>1615</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.6.1615</pub-id><pub-id pub-id-type="pmid">15919781</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Bortolotti</surname><given-names>N</given-names></name><name><surname>Motz</surname><given-names>E</given-names></name><name><surname>Pieri</surname><given-names>C</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Tonutti</surname><given-names>L</given-names></name><name><surname>Lizzio</surname><given-names>S</given-names></name><name><surname>Feletto</surname><given-names>F</given-names></name><name><surname>Catone</surname><given-names>B</given-names></name><name><surname>Taboga</surname><given-names>C</given-names></name></person-group><article-title>Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia</article-title><source>Metabolism</source><year>1999</year><volume>48</volume><issue>12</issue><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1016/S0026-0495(99)90237-8</pub-id><pub-id pub-id-type="pmid">10599980</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>KB</given-names></name><name><surname>Ames</surname><given-names>BN</given-names></name></person-group><article-title>Oxidative decay of DNA</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><issue>32</issue><fpage>19633</fpage><lpage>19636</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.32.19633</pub-id><pub-id pub-id-type="pmid">9289489</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group><article-title>Oxidative stress and cancer: have we moved forward?</article-title><source>Biochem J</source><year>2007</year><volume>401</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1042/BJ20061131</pub-id><pub-id pub-id-type="pmid">17150040</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieri</surname><given-names>S</given-names></name><name><surname>Muti</surname><given-names>P</given-names></name><name><surname>Claudia</surname><given-names>A</given-names></name><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Pala</surname><given-names>V</given-names></name><name><surname>Grioni</surname><given-names>S</given-names></name><name><surname>Abagnato</surname><given-names>CA</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Contiero</surname><given-names>P</given-names></name><name><surname>Schunemann</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Prospective study on the role of glucose metabolism in breast cancer occurrence</article-title><source>Int J Cancer</source><year>2012</year><volume>130</volume><issue>4</issue><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1002/ijc.26071</pub-id><pub-id pub-id-type="pmid">21413010</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minicozzi</surname><given-names>P</given-names></name><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Sebastiani</surname><given-names>F</given-names></name><name><surname>Falcini</surname><given-names>F</given-names></name><name><surname>Vattiato</surname><given-names>R</given-names></name><name><surname>Cioccoloni</surname><given-names>F</given-names></name><name><surname>Calagreti</surname><given-names>G</given-names></name><name><surname>Fusco</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>MF</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><etal/></person-group><article-title>High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><issue>18</issue><fpage>3881</fpage><lpage>3888</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.08.004</pub-id><pub-id pub-id-type="pmid">24011933</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O</given-names></name></person-group><article-title>On respiratory impairment in cancer cells</article-title><source>Science</source><year>1956</year><volume>124</volume><issue>3215</issue><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">13351639</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name></person-group><article-title>The potential role of transformation-induced metabolic changes in tumor-host interaction</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><issue>18</issue><fpage>4151</fpage><lpage>4156</lpage><pub-id pub-id-type="pmid">7664293</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fais</surname><given-names>S</given-names></name><name><surname>Venturi</surname><given-names>G</given-names></name><name><surname>Gatenby</surname><given-names>B</given-names></name></person-group><article-title>Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy</article-title><source>Cancer Metastasis Rev</source><year>2014</year><volume>33</volume><issue>4</issue><fpage>1095</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1007/s10555-014-9531-3</pub-id><pub-id pub-id-type="pmid">25376898</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McTiernan</surname><given-names>A</given-names></name><name><surname>Tworoger</surname><given-names>SS</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Rajan</surname><given-names>KB</given-names></name><name><surname>Sorensen</surname><given-names>B</given-names></name><name><surname>Rudolph</surname><given-names>RE</given-names></name><name><surname>Bowen</surname><given-names>D</given-names></name><name><surname>Stanczyk</surname><given-names>FZ</given-names></name><etal/></person-group><article-title>Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>8</issue><fpage>2923</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3393</pub-id><pub-id pub-id-type="pmid">15087413</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedenreich</surname><given-names>CM</given-names></name><name><surname>Neilson</surname><given-names>HK</given-names></name><name><surname>Woolcott</surname><given-names>CG</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ballard-Barbash</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><name><surname>Stanczyk</surname><given-names>FZ</given-names></name><name><surname>Brant</surname><given-names>RF</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women</article-title><source>Endocr Relat Cancer</source><year>2011</year><volume>18</volume><issue>3</issue><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1530/ERC-10-0303</pub-id><pub-id pub-id-type="pmid">21482635</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Ennis</surname><given-names>M</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Trudeau</surname><given-names>ME</given-names></name><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Madarnas</surname><given-names>Y</given-names></name><name><surname>Hartwick</surname><given-names>W</given-names></name><name><surname>Hoffman</surname><given-names>B</given-names></name><name><surname>Hood</surname><given-names>N</given-names></name></person-group><article-title>Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><issue>1</issue><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.1.42</pub-id><pub-id pub-id-type="pmid">11773152</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Sestak</surname><given-names>I</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><collab>Investigators AL</collab></person-group><article-title>Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><issue>12</issue><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70257-6</pub-id><pub-id pub-id-type="pmid">21087898</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byberg</surname><given-names>L</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>McKeigue</surname><given-names>PM</given-names></name><name><surname>Lithell</surname><given-names>HO</given-names></name></person-group><article-title>Changes in physical activity are associated with changes in metabolic cardiovascular risk factors</article-title><source>Diabetologia</source><year>2001</year><volume>44</volume><issue>12</issue><fpage>2134</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1007/s001250100022</pub-id><pub-id pub-id-type="pmid">11793014</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>KL</given-names></name><name><surname>Degarmo</surname><given-names>R</given-names></name><name><surname>Langley</surname><given-names>J</given-names></name><name><surname>McMahon</surname><given-names>C</given-names></name><name><surname>Howley</surname><given-names>ET</given-names></name><name><surname>Bassett</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Thompson</surname><given-names>DL</given-names></name></person-group><article-title>Increasing daily walking lowers blood pressure in postmenopausal women</article-title><source>Med Sci Sports Exerc</source><year>2001</year><volume>33</volume><issue>11</issue><fpage>1825</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.1097/00005768-200111000-00005</pub-id><pub-id pub-id-type="pmid">11689731</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Mayer-Davis</surname><given-names>EJ</given-names></name><name><surname>Addy</surname><given-names>CL</given-names></name><name><surname>Pate</surname><given-names>RR</given-names></name><name><surname>Durstine</surname><given-names>JL</given-names></name><name><surname>Stolarczyk</surname><given-names>LM</given-names></name><name><surname>Ainsworth</surname><given-names>BE</given-names></name></person-group><article-title>Moderate-intensity physical activity and fasting insulin levels in women: the cross-cultural activity participation study</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><issue>4</issue><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.4.449</pub-id><pub-id pub-id-type="pmid">10857933</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KL</given-names></name><name><surname>Foster-Schubert</surname><given-names>KE</given-names></name><name><surname>Makar</surname><given-names>KW</given-names></name><name><surname>Kratz</surname><given-names>M</given-names></name><name><surname>Hagman</surname><given-names>D</given-names></name><name><surname>Schur</surname><given-names>EA</given-names></name><name><surname>Habermann</surname><given-names>N</given-names></name><name><surname>Horton</surname><given-names>M</given-names></name><name><surname>Abbenhardt</surname><given-names>C</given-names></name><name><surname>Kuan</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Gene expression changes in adipose tissue with diet- and/or exercise-induced weight loss</article-title><source>Cancer Prev Res</source><year>2013</year><volume>6</volume><issue>3</issue><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-12-0212</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulun</surname><given-names>SE</given-names></name><name><surname>Zeitoun</surname><given-names>K</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><name><surname>Simpson</surname><given-names>ER</given-names></name></person-group><article-title>Aromatase in aging women</article-title><source>Semin Reprod Endocrinol</source><year>1999</year><volume>17</volume><issue>4</issue><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1016244</pub-id><pub-id pub-id-type="pmid">10851574</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>SB</given-names></name><name><surname>Gorham</surname><given-names>ED</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hofflich</surname><given-names>H</given-names></name><name><surname>Garland</surname><given-names>CF</given-names></name></person-group><article-title>Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer</article-title><source>Anticancer Res</source><year>2014</year><volume>34</volume><issue>3</issue><fpage>1163</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">24596354</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>CF</given-names></name><name><surname>Gorham</surname><given-names>ED</given-names></name><name><surname>Mohr</surname><given-names>SB</given-names></name><name><surname>Grant</surname><given-names>WB</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Lipkin</surname><given-names>M</given-names></name><name><surname>Newmark</surname><given-names>H</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Garland</surname><given-names>FC</given-names></name></person-group><article-title>Vitamin D and prevention of breast cancer: pooled analysis</article-title><source>J Steroid Biochem Mol Biol</source><year>2007</year><volume>103</volume><issue>3&#x02013;5</issue><fpage>708</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2006.12.007</pub-id><pub-id pub-id-type="pmid">17368188</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">SIOMMMS Guidelines. Linee guida 2015 per la diagnosi, prevenzione e terapia dell'osteoporosi. <ext-link ext-link-type="uri" xlink:href="http://www.siommms.it/wp-content/uploads/2015/11/Linee-guida-OP_2015.pdf">http://www.siommms.it/wp-content/uploads/2015/11/Linee-guida-OP_2015.pdf</ext-link>.</mixed-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forouhi</surname><given-names>NG</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Rickard</surname><given-names>AP</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Luben</surname><given-names>R</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name></person-group><article-title>Circulating 25-hydroxyvitamin D concentration and the risk of type two diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><issue>8</issue><fpage>2173</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1007/s00125-012-2544-y</pub-id><pub-id pub-id-type="pmid">22526608</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>SL</given-names></name><name><surname>Baggerly</surname><given-names>LL</given-names></name><name><surname>French</surname><given-names>CB</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name><name><surname>Gorham</surname><given-names>ED</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Scragg</surname><given-names>R</given-names></name><name><surname>Garland</surname><given-names>CF</given-names></name></person-group><article-title>Incidence rate of type two diabetes is &#x0003e;50% lower in GrassrootsHealth cohort with median serum 25-hydroxyvitamin D of 41&#x000a0;ng/ml than in NHANES cohort with median of 22&#x000a0;ng/ml</article-title><source>J Steroid Biochem Mol Biol</source><year>2016</year><volume>155</volume><issue>Pt B</issue><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.06.013</pub-id><pub-id pub-id-type="pmid">26151742</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabaaij</surname><given-names>L</given-names></name><name><surname>van den Akker</surname><given-names>M</given-names></name><name><surname>Schellevis</surname><given-names>FG</given-names></name></person-group><article-title>Excess of health care use in general practice and of comorbid chronic conditions in cancer patients compared to controls</article-title><source>BMC Fam Pract</source><year>2012</year><volume>13</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/1471-2296-13-60</pub-id><pub-id pub-id-type="pmid">22712888</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louwman</surname><given-names>WJ</given-names></name><name><surname>Aarts</surname><given-names>MJ</given-names></name><name><surname>Houterman</surname><given-names>S</given-names></name><name><surname>van Lenthe</surname><given-names>FJ</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Janssen-Heijnen</surname><given-names>ML</given-names></name></person-group><article-title>A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status</article-title><source>Br J Cancer</source><year>2010</year><volume>103</volume><issue>11</issue><fpage>1742</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605949</pub-id><pub-id pub-id-type="pmid">20978508</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redig</surname><given-names>AJ</given-names></name><name><surname>Munshi</surname><given-names>HG</given-names></name></person-group><article-title>Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy</article-title><source>Am J Med</source><year>2010</year><volume>123</volume><issue>1</issue><fpage>87</fpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2009.06.022</pub-id><pub-id pub-id-type="pmid">20102997</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>NF</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>E</given-names></name><name><surname>Austoker</surname><given-names>J</given-names></name><name><surname>Rose</surname><given-names>PW</given-names></name></person-group><article-title>Long-term survivors of adult cancers and uptake of primary health services: a systematic review</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><issue>2</issue><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2007.10.005</pub-id><pub-id pub-id-type="pmid">18035534</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Vyas</surname><given-names>A</given-names></name><name><surname>Escalante</surname><given-names>C</given-names></name><name><surname>Weiser</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Geraci</surname><given-names>JM</given-names></name></person-group><article-title>Results of general internal medicine consultations for diabetes mellitus in 283 cancer patients</article-title><source>Am J Med Sci</source><year>2007</year><volume>333</volume><issue>5</issue><fpage>276</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e31805340d4</pub-id><pub-id pub-id-type="pmid">17505168</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women</article-title><source>Am J Clin Nutr</source><year>2002</year><volume>75</volume><issue>3</issue><fpage>492</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">11864854</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Holmes</surname><given-names>MD</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name></person-group><article-title>Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women</article-title><source>Am J Clin Nutr</source><year>2001</year><volume>73</volume><issue>3</issue><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">11237932</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Lindstrom</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>JG</given-names></name><name><surname>Valle</surname><given-names>TT</given-names></name><name><surname>Hamalainen</surname><given-names>H</given-names></name><name><surname>Ilanne-Parikka</surname><given-names>P</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname><given-names>S</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Louheranta</surname><given-names>A</given-names></name><name><surname>Rastas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevention of type two diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>18</issue><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1056/NEJM200105033441801</pub-id><pub-id pub-id-type="pmid">11333990</pub-id></element-citation></ref></ref-list></back></article>